
International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 76

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–113) and Recommended (1–74) International Nonproprietary Names can be found in *Cumulative List No. 16, 2015* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 76

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–113) et recommandées (1–74) dans la *Liste récapitulative No. 16, 2015* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 76

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–113) y Recomendadas (1–74) se encuentran reunidas en *Cumulative List No. 16, 2015* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:
Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

acebilustatum

acebilustat

4-[[[(1S,4S)-5-({4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl)methyl}-2,5-diazabicyclo[2.2.1]heptan-2-yl)methyl]benzoic acid


acébilustat

acide 4-[[[(1S,4S)-5-({4-[4-(1,3-oxazol-2-yl)phénoxy]phényl)méthyl}-2,5-diazabicyclo[2.2.1]heptan-2-yl)méthyl]benzoïque

acebilustat

ácido 4-[[[(1S,4S)-5-({4-[4-(1,3-oxazol-2-il)fenoxi]fenil)metil]-2,5-diazabicyclo[2.2.1]heptan-2-il]metil]benzoico

C₂₉H₂₇N₃O₄



alalevonadifloxacinum

alalevonadifloxacin

(5S)-8-[4-(L-alanyloxy)piperidin-1-yl]-9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid


alalévonadifloxacine

acide (5S)-8-[4-(L-alanyloxy)pipéridin-1-yl]-9-fluoro-5-méthyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylique

alalevonadifloxacino

ácido (5S)-8-[4-(L-alaniloxi)piperidin-1-il]-9-fluoro-5-metil-1-oxo-6,7-dihidro-1H,5H-pirido[3,2,1-ij]quinolina-2-carboxílico

C₂₂H₂₆FN₃O₅



albusomatropinum #

albusomatropin

human serum albumin (residues 1-585) fusion protein with human somatotropin (growth hormone) (residues 586-776), produced in yeast cells (*Saccharomyces cerevisiae*)

albusomatropine

albumine sérique humaine (résidus 1-585) protéine de fusion avec la somatotropine humaine (hormone de croissance) (résidus 586-776), produit par culture de levure (*Saccharomyces cerevisiae*)

albusomatropina

albúmina sérica humana (restos 1-585) proteína de fusión con la somatotropina humana (hormona de crecimiento) (restos 586-776), producida mediante cultivo de levadura (*Saccharomyces cerevisiae*)

Sequence/ Séquence / Secuencia

```

DAHKSEVAHR FKDLGEENFK ALVLIAFAQY LQQCPFEDHV KLVNEVTEFA 50
KTCVADESSE NCDKSLHTLF GDKLCTVATL RETYGMADC CAKQEPERNE 100
CFLQHKDDNP NLPRLVREPV DVMCTAFHDN EETFLKKYLY EIARRHPYFY 150
APELLFFAKR YKAAFTCCQ AADKAACLLP KLDELDEGK ASSAKQRLKC 200
ASLQKFGERA FKAWAVARLS QRFPAKEFAE VSKLVTDLTK VHTCCCHGDL 250
LECADDRADL AKYICENQDS ISSKKECFE KPLLEKSHCI AEVENDEMPA 300
DLPSLAADFV ESKDVCKNYA EAKDVFLGMP LYEYARRHPD YSVVLLRLA 350
KTYETTLKCK CAADPHECY AKVFDEFKPL VEEPQNLIKQ NCELFEQLGE 400
YKFQNALVRV YTKKVPQVST PTLVEVSRLN KGVGSKCKKH PEAKRMPCAE 450
DYLVSVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA LEVDETYVPK 500
EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD 550
FAAFVEKCKC ADDKETCFAE EGKKLVAASQ AALGLFPTIP LSRLFDNAML 600
RAHRLHQLAF DTYQEFEEAY IPKEQKYSFL QNPQTSLCFS ESIPFPSNRE 650
ETQQKSNLEL LRISLLLIQS WLEPVQFLRS VFANSLVYGA SDSNVYDLLK 700
DLEEGIQITL GRLEDGSPRT GQIFKQTSYK FDTNSHNDAA LLKNYGLLYC 750
FRKMDMKVET FLRIVQCRSV EGSCGF 776

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

53-62 75-91 90-101 124-169 168-177 200-246 245-253
 265-279 278-289 316-361 360-369 392-438 437-448 461-477
 476-487 514-559 558-567 638-750 767-774

asunerceptum #

asunercept

fusion protein for immune applications (FPIA) comprising the *Homo sapiens* FAS (Fas cell surface death receptor, TNFRSF6, tumor necrosis factor receptor (TNFR) superfamily member 6, FAS1, APO-1, CD95) extracellular domain, fused with *Homo sapiens* immunoglobulin G1 Fc fragment;

Homo sapiens FAS precursor fragment 26-172 (1-147) - gamma1 chain H-CH2-CH3 fragment [*Homo sapiens* IGHG1*03 (hinge 5-15 (148-158), CH2 (159-268), CH3 (269-373), CHS (374-375))] (148-375); dimer (148-148':154-154':157-157')-trisdisulfide

asunercept

protéine de fusion pour applications immunitaires (FPIA) comprenant le domaine extracellulaire d'*Homo sapiens* FAS (récepteur de mort membranaire Fas, TNFRSF6, membre 6 de la superfamille des récepteurs du facteur de nécrose tumorale (TNFR), FAS1, APO-1, CD95), fusionné au fragment Fc de l'immunoglobuline G1 d'*Homo sapiens*; *Homo sapiens* FAS fragment 26-172 du précurseur (1-147)-fragment H-CH2-CH3 de la chaîne gamma1 [*Homo sapiens* IGHG1*03 (charnière 5-15 (148-158), CH2 (159-268), CH3 (269-373), CHS (374-375))] (148-375); dimère (148-148':154-154':157-157')-trisdisulfure

asunercept

proteína de fusión para aplicaciones inmunitarias (FPIA) que comprende el dominio extracelular de *Homo sapiens* FAS (receptor de muerte Fas de membrana, TNFRSF6, miembro 6 de la superfamilia de receptores del factor de necrosis tumoral (TNFR), FAS1, APO-1, CD95), fusionado con el fragmento Fc de la inmunoglobulina G1 de *Homo sapiens*;
FAS de *Homo sapiens* fragmento 26-172 del precursor (1-147) -fragmento H-CH2-CH3 de la cadena gamma1 [*Homo sapiens* IGHG1*03 (bisagra 5-15 (148-158), CH2 (159-268), CH3 (269-373), CHS (374-375))] (148-375); dímero (148-148':154-154':157-157')-trisdисульфuro

Fused chain / chaîne fusionnée / cadena fusiónada

```
QVTDINSKGL ELRKTVTTFE TQNLEGLHHD QFCHKPCPP GERKARDCTV 50
NGDEPDCVFC QEGKEYTDKA HFSSKCRRCR LCDEGHGLEV EINCTRTQNT 100
KCRCKPNFFC NSTVCEHCDF CTKECHGIK ECTLTSNTKC KEGGRSCDK 150
THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE 200
VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNKEYKCK 250
VSNKALPAPI EKTISKAKGQ PREPQVYTLF PSREEMTKNQ VSLTCLVKGK 300
YPSDIAVEWE SNGQPENNYK TTPPVLDSDG SFFLYSKLTV DKSRWQQGNV 350
FSCVMHEAL HNHYTQKSL SLPFGK 375
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intrachain FAS 34-48 38-57 60-76 79-94
82-102 104-118 121-132 124-140
34'-48' 38'-57' 60'-76' 79'-94'
82'-102' 104'-118' 121'-132' 124'-140'
IGHG1 (C23-C104) 189-249 295-353
189'-249' 295'-353'
```

Interchain IGHG1 (h5, h 11, h 14) 148-148' 154-154' 157-157'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

FAS:
93, 111, 93', 111': complex mono-, bi-, tri- and tetra-antennary oligosaccharides, partially sialylated, oligosaccharides complexes de structure ramifiée (de 1 à 4 branches), partiellement sialylés, oligosacáridos complejos mono-bi, tri y tetra-anténado, parcialmente sialilados
IGHG1 CH2 N84.4:
225, 225': complex mono- and biantennary non-sialylated oligosaccharides, oligosaccharides complexes de structure ramifiée (de 1 à 2 branches) non-sialylés, oligosacáridos complejo mono- and bianténado non-sialilado

Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales:

H CHS K2 C-terminal lysine clipping, coupure de la lysine C-terminale, supresión de lisina C-terminal: 375, 375'

avacopanum

avacopan

(2*R*,3*S*)-2-[4-(cyclopentylamino)phenyl]-1-(2-fluoro-6-methylbenzoyl)-*N*-[4-methyl-3-(trifluoromethyl)phenyl]piperidine-3-carboxamide


avacopan

(2*R*,3*S*)-2-[4-(cyclopentylamino)phényl]-1-(2-fluoro-6-méthylbenzoyl)-*N*-[4-méthyl-3-(trifluorométhyl)phényl]pipéridine-3-carboxamide

avacopán

(2*R*,3*S*)-2-[4-(ciclopentilamino)fenil]-1-(2-fluoro-6-metilbenzoi)-*N*-[4-metil-3-(trifluorometil)fenil]piperidina-3-carboxamida

C₃₃H₃₅F₄N₃O₂

**bazilitoranum**

bazilitoran

all-P-ambo-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O-methyl-P-thioguanilyl-(3'→5')-2'-O-methyl-P-thiouridylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-7-carba-2'-deoxy-P-thioguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O-methyl-P-thioguanilyl-(3'→5')-2'-O-methyluridine

bazilitoran

tout-P-ambo-2'-déoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioadénylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O-méthyl-P-thioguanilyl-(3'→5')-2'-O-méthyl-P-thiouridylyl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-7-carba-2'-déoxy-P-thioguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-O-méthyl-P-thioguanilyl-(3'→5')-2'-O-méthyluridine

bazilitorán

todo-P-ambo-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metil-P-tiouridilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-7-carba-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-O-metil-P-tioguanilil-(3'→5')-2'-O-metiluridina

C₁₇₉H₂₃₃N₅₂O₁₀₁P₁₇S₁₇

(3'→5')d(P-thio)(C-T-A-T-C-T-rGm-rUm-m5C-c7G-T-T-C-T-C-T-rGm-rUm)

Legend:

rGm = 2'-O-méthylguanosine

rUm = 2'-O-méthyluridine

m5C = 2'-deoxy-5-méthylcytidine

c7G = 2'-deoxy-7-carbaguanosine (C replaces N)

bevacizumabum beta #

bevacizumab beta

immunoglobulin G1-kappa, anti-[*Homo sapiens* VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)], humanized monoclonal antibody;

gamma1 heavy chain (1-453) [humanized VH (*Homo sapiens* IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 (CH1 R120>K (220) (124-221), hinge (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (232-232":235-235")-bisdisulfide

bêvacizumab bêta

immunoglobuline G1-kappa, anti-[*Homo sapiens* VEGFA (facteur de croissance A de l'endothélium vasculaire, VEGF-A, VEGF)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-453) [VH humanisé (*Homo sapiens* IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 (CH1 R120>K (220) (124-221), charnière (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (232-232":235-235")-bisdisulfure

bevacizumab beta

immunoglobulina G1-kappa, anti-[*Homo sapiens* VEGFA (factor de crecimiento A endotelial vascular, VEGF-A, VEGF)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-453) [VH humanizado (*Homo sapiens* IGHV3-30*02 (76.80%) -(IGHD) -IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 (CH1 R120>K (220) (124-221), bisagra (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (88.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (232-232":235-235")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGYTFT NYGMNWRQA PGKLEWVGW 50
INTYTGTEPT AADFKRRFTF SLDTSKSTAY LQMNSLRAED TAVYCAKYP 100
HYYGSSHWFY DWGQGTLTVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFFPAVL QSSGLYSLSS VTVFSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPCPAPEL LGGFSVFLFP 250
PKPKDTLMIS RTPVETCVVV DVSHEDPEVK FNNYVDGVEV HNAKTKPRE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTKQSLSL 450
PGK 453
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVT ITCSAQDIS NYLNWYQKPK GKAPKVLIF 50
TSSLHSGVPS RFGSGSGSDT FTLTISLQPF EDFATYYCQQ YSTVPWTFGQ 100
GTRVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYERKH VYACEVTHQG 200
LSSPVTKSPN RGE 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H (C23-C104) 22-96 150-206 267-327 373-431
22"-96" 150"-206" 267"-327" 373"-431"
Intra-L (C23-C104) 23"-88" 134"-194"
23"-88" 134"-194"
Inter-H-L (h 5-CL 126) 226-214' 226"-214"
Inter-H-H (h 11, h 14) 232-232" 235-235"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84,4;

303, 303"

Fucosylated complex bi-antennary CHO-type glycans, with a level of galactosylated A2G2F > 1.5% and of high mannose Man5 > 0.9% / glycanes de type CHO bi-antennaires complexes fucosylés, avec un taux de galactosylé A2G2F > 1.5% et de riche en mannose Man5 > 0.9% / glicanos de tipo CHO biantenararios complejos fucosilados, con una tasa de galactosilado A2G2F > 1.5% y de alta manosa Man5 > 0.9%

blontuvmabum #
blontuvmab

immunoglobulin G2_V-kappa-C-lambda, anti-[*Homo sapiens* MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)], caninized monoclonal antibody;
gamma2 heavy chain chimeric (1-448) [*Mus musculus* VH (*Mus musculus* IGHV1-15*01 -(IGHD) -IGHJ1*03) [8.8.6] (1-113) -*Canis lupus familiaris* IGHG2*02 (CH1 T26>Q (131) (114-211), hinge (212-229), CH2 (230-339), CH3 (340-446), CHS (447-448)) (114-448)], (128-218')-disulfide with V-kappa-C-lambda light chain chimeric (1'-219') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-112') -*Canis lupus familiaris* IGL1CS1*01 V45.3>I (162) (114'-219')]; dimer (225-225'':228-228'')-bisdisulfide

blontuvmab

immunoglobuline G2_V-kappa-C-lambda, anti-[*Homo sapiens* MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)], anticorps monoclonal caninisé;
chaîne lourde gamma2 chimérique (1-448) [*Mus musculus* VH (*Mus musculus* IGHV1-15*01 -(IGHD) -IGHJ1*03) [8.8.6] (1-113) -*Canis lupus familiaris* IGHG2*02 (CH1 T26>Q (131) (114-211), charnière (212-229), CH2 (230-339), CH3 (340-446), CHS (447-448)) (114-448)], (128-218')-disulfure avec la chaîne légère V-kappa-C-lambda chimérique (1'-219') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-112') -*Canis lupus familiaris* IGL1CS1*01 V45.3>I (162) (114'-219')]; dimère (225-225'':228-228'')-bisdisulfure

blontuvmab

inmunoglobulina G2_V-kappa-C-lambda, anti-[*Homo sapiens* MS4A1 (miembro 1 de la subfamilia A con 4 dominios transmembranarios, CD20)], anticuerpo monoclonal caninizado;
cadena pesada gamma2 quimérica (1-448) [*Mus musculus* VH (*Mus musculus* IGHV1-15*01 -(IGHD) -IGHJ1*03) [8.8.6] (1-113) -*Canis lupus familiaris* IGHG2*02 (CH1 T26>Q (131) (114-211), bisagra (212-229), CH2 (230-339), CH3 (340-446), CHS (447-448)) (114-448)], (128-218')-disulfuro con la cadena ligera V-kappa-C-lambda quimérica (1'-219') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-112') -*Canis lupus familiaris* IGL1CS1*01 V45.3>I (162) (114'-219')]; dímero (225-225'':228-228'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQQSRAE LVRPGASVTL SCKPSGYTFT DYEYVHWKQT PVHGLEWIGA 50
 IDPETGGTAD NQKFKGKAIL TADKSSSTAY MELRSLTSED SAVYYCTNEV 100
 DVWGTGTTVT VSSASTTAPS VFPLAPSCGS QSGSTVALAC LVSGYFPEPV 150
 TVSWNSGSLT SGVHTFFSVL QSSGLYSLSS MVTVPSSRWP SETFTCNVAH 200
 PASKTKVDKP VPKRENGRVP RPPDCPKCPA FEMLGGSVF IFPPKPKDTL 250
 LIARTFEVTC VVVDLDFEDP EVQISWFVDG KQMQTAKTQP REEQFNGTYR 300
 VVSVLPIGHQ DWLKGKQFTC KVNKKALPSP IERTISKARG QAHQPSVYVL 350
 PPSREELSKN TVSLTCLIKD FFPDIDVEW QSNQQEPES KYRTTPPQLD 400
 EDGSYFLYSK LSVDKSRWQR GDTFICAVMH EALNHNYTQR SLSHSPGK 448

Light chain / Chaîne légère / Cadena ligera

DVVMSSQSPSS LAVSVGEKVT MSCKSSQSLT YSGNQKNYLA WYQQKPGQSP 50
 RLLIYWASTR ESGVPRDFTG SSGTDFTLT ISSVKAEDLA VFYCCQYYNY 100
 PLTFGGGTHL TVLGQPKASP SVTLFPSSSE ELGANKATLV CLISDFYPSG 150
 VTVAMKADGS PITQGVETTK PSKQSNKKYA ASSYLSLTPD KWKSHSFPSC 200
 LVTHEGSTVE KKVAPAECG 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 140-196 260-320 366-426
 22"-96" 140"-196" 260"-320" 366"-426"
 Intra-L (C23-C104) 23"-94" 141"-200
 23"-94" 141"-200"
 Inter-H-L (CH1 11-CL 126) 128-218" 128"-218"
 Inter-H-H (h 14, h 17) 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 296, 296"

brimapidum
brimapidide

D-α-aspartyl-D-glutaminyl-D-seryl-D-arginyl-D-prolyl-D-valyl-
 D-glutaminyl-D-prolyl-D-phenylalanyl-D-leucyl-
 D-asparaginy-D-leucyl-D-threonyl-D-threonyl-D-prolyl-
 D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-D-prolyl-
 D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-
 D-arginyl-D-lysyl-D-lysyl-D-arginylglycinamide

brimapidide

D-α-aspartyl-D-glutaminyl-D-séryl-D-arginyl-D-prolyl-D-valyl-
 D-glutaminyl-D-prolyl-D-phénylalanil-D-leucyl-
 D-asparaginy-D-leucyl-D-thréonyl-D-thréonyl-
 D-prolyl-D-arginyl-D-lysyl-D-prolyl-D-arginyl-D-prolyl-
 D-prolyl-D-arginyl-D-arginyl-D-arginyl-D-glutaminyl-D-arginyl-
 D-arginyl-D-lysyl-D-lysyl-D-arginylglycinamide

brimapidida

D-α-aspartil-D-glutaminil-D-seril-D-arginil-D-prolil-
 D-valil-D-glutaminil-D-prolil-D-fenilalanil-D-leucil-
 D-asparaginil-D-leucil-D-treonil-D-treonil-D-prolil-
 D-arginil-D-lisil-D-prolil-D-arginil-D-prolil-D-prolil-
 D-arginil-D-arginil-D-arginil-D-glutaminil-D-arginil-
 D-arginil-D-lisil-D-lisil-D-arginilglycinamida

C₁₆₄H₂₈₆N₆₆O₄₀

D-Aminoacids sequence / Séquence des D-aminoacides /
 Secuencia de D-aminoácidos

DQSRPVPQFPL NLTPRKPRP PRRRQRRKKR G 31

Modified residue / Résidu modifié / Resto modificado

G = glycinamide

cabiralizumabum #

cabiralizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* CSF1R (colony stimulating factor 1 receptor, CSF-1R, CSF-1-R, macrophage colony-stimulating factor 1 receptor, c-fms, FMS, CD115)], humanized monoclonal antibody; gamma4 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), hinge S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-111') - *Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (228-228":231-231")-bisdisulfide

cabiralizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* CSF1R (récepteur du facteur 1 stimulant de colonies, CSF-1R, CSF-1-R, récepteur du facteur 1 stimulant des colonies de macrophages, c-fms, FMS, CD115)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-449) [VH humanisé (*Homo sapiens* IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), charnière S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-111') - *Homo sapiens* IGKC*01, Km3 (112'-218')]; dimère (228-228":231-231")-bisdisulfure

cabiralizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* CSF1R (receptor del factor 1 de estimulación de colonias, CSF-1R, CSF-1-R, receptor del factor 1 de estimulación de colonias de macrófagos, c-fms, FMS, CD115)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-449) [VH humanizado (*Homo sapiens* IGHV1-46*01 (83.70%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122)), IGHG4*01 (CH1 (123-220), bisagra S10>P (230) (221-232), CH2 (233-342), CH3 (343-447), CHS (448-449)) (123-449)], (136-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV3-11*01 (84.90%) -IGKJ4*01) [10.3.9] (1'-111') - *Homo sapiens* IGKC*01, Km3 (112'-218')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DNYMIWVRQA PGQGLEWMGD 50
 INPYNGGTF NQKFKGRVTI TADKSTSTAY MELSSLRSED TAVVYCARES 100
 PYFSNLYVMD YWGQGLTLTV SSASTKGPSV FPLAPCSRST SESTAALGCL 150
 VKDYFPEPVT VSWNSGALTS GVHTFFAVLQ SSGLYSLSSV VTFVSSSLGT 200
 KTYTCNVDHK PSNTKVDKRV ESKYGPCCPF CPAPEFLGGP SVFLFPKPK 250
 DTLMISRTPE VTCVVVDVSQ EDPEVQFNWY VDGVEVHNAK TKPREEQFNS 300
 TYRVVSVLTV LHQDWLNGKE YKCKVSNKGL PSSIEKTISK AKGQPREPQV 350
 YTLPPSQEEM TKNQVSLTCL VKGFPYSDIA VEWESNGQPE NNYKTTPEVL 400
 DSDGSSFLYS RLTVDKSRWQ EGNVFSCSVM HEALHNHYTQ KSLSLSLGK 449

Light chain / Chaîne légère / Cadena ligera
 EIVLTQSPAT LSLSPGERAT LSCASQSV DGDNYMNYWY QQKFGQAPRL 50
 LIYAASNLES GIPARFSGSG SGTDFTLTIS SLEPEDFAVY YCHLSNEDLS 100
 TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGASVVCLL NNFYPREAKV 150
 QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLKADY EKHKVYACEV 200
 THQGLSSPVT KSFNRGEC 218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 149-205 263-323 369-427
 22*-96* 149*-205* 263*-323* 369*-427*
 Intra-L (C23-C104) 23*-92* 138*-198*
 23***-92** 138***-198**
 Inter-H-L (CH1 10-CL 126) 136-218 136*-218*
 Inter-H-H (h 8, h 11) 228-228* 231-231*

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 299, 299*
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

carotuximabum #
 carotuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* ENG (endoglin, Osler-Rendu-Weber syndrome 1, ORW1, ORW, HHT1, CD105)], chimeric monoclonal antibody; gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV6-6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-213')-disulfide with kappa light chain (1'-213')] [chimeric V-KAPPA (*Mus musculus* IGKV4-72*01 -*Homo sapiens* IGKJ5*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213'))]; dimer (227-227'':230-230'')-bisdisulfide

carotuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* ENG (endogline, syndrome 1 d'Osler-Rendu-Weber, ORW1, ORW, HHT1, CD105)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV6-6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-213')-disulfure avec la chaîne légère kappa (1'-213')] [V-KAPPA chimérique (*Mus musculus* IGKV4-72*01 -*Homo sapiens* IGKJ5*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213'))]; dimère (227-227'':230-230'')-bisdisulfure

carotuximab

immunoglobulina G1-kappa, anti-[*Homo sapiens* ENG (endoglina, síndrome 1 de Osler-Rendu-Weber, ORW1, ORW, HHT1, CD105)], anticuerpo monoclonal quimérico;

cadena pesada gamma1 (1-448) [*Mus musculus* VH (IGHV6-6*01 -(IGHD) -IGHJ2*01) [8.10.9] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), bisagra (217-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (119-448)], (221-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA quimérico (*Mus musculus* IGKV4-72*01 -*Homo sapiens* IGKJ5*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

EVKLEESGGG LVQPGGSMKL SCAASGFTFS DAWMDWVRQS PEKGLEWVAE 50
IRSKASNHAT YYAESVKGRF TISRDDSKSS VYLQMNLSLA EDTGIYYCTR 100
WRRFDDSWGQ GTTLTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPPEPVTWSN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKFSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTPVLD 400
SDGSFFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448

```

Light chain / Chaîne légère / Cadena ligera

```

QIVLSQSPAI LSASPGKVT MTCRASSVS YMHYQQKPG SSPKPIYAT 50
SNLASGVPR FSGSGSGTSY SLTISRVEAE DAATYYCQW SSNFLTFGAG 100
TKLELKRVA APSVFI FPPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSTLTLL SKADYERHKV YACEVTHQGL 200
SSPVTKSFNR GEC 213

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-98	145-201	262-322	368-426
	22"-98"	145"-201"	262"-322"	368"-426"
Intra-L (C23-C104)	23'-87'	133'-193'		
	23"-87"	133"-193"		
Inter-H-L (h 5-CL 126)	221-213'	221"-213"		
Inter-H-H (h 11, h 14)	227-227"	230-230"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

298, 298"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenaríos complejos fucosilados

cefiderocolum

cefiderocol


(6*R*,7*R*)-7-[(2*Z*)-2-(2-amino-1,3-thiazol-4-yl)-2-[[[2-carboxypropan-2-yl)oxy]imino]acetamido]-3-{{1-[2-(2-chloro-3,4-dihydroxybenzamido)ethyl]pyrrolidin-1-ium-1-yl)methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

céfidérocol

(6*R*,7*R*)-7-[(2*Z*)-2-(2-amino-1,3-thiazol-4-yl)-2-[[[2-carboxypropan-2-yl)oxy]imino]acétamido]-3-{{1-[2-(2-chloro-3,4-dihydroxybenzamido)éthyl]pyrrolidin-1-ium-1-yl)méthyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate

cefiderocol

(6*R*,7*R*)-7-[(2*Z*)-2-(2-amino-1,3-thiazol-4-il)-2-[[[2-carboxipropán-2-il)oxi]imino]acetamido]-3-{{1-[2-(2-cloro-3,4-dihidroxibenzamido)etil]pirrolidin-1-ium-1-il)métíl}-8-oxo-5-tia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxilato





cemisiranum
cemdisiran

duplex of [(2*S*,4*R*)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy)methyl}-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl)-4-hydroxypyrrolidin-2-yl]methyl hydrogen *all-P-ambo*-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-*O*-methyl-*P*-thioadenylyl-(3'→5')-2'-deoxy-2'-fluoroguanlyl-(3'→5')-2'-*O*-methylcytidyl-(3'→5')-2'-deoxy-2'-fluoroadenylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanlyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyladenylyl-(3'→5')-2'-*O*-methyluridylyl-(3'→5')-2'-*O*-methyl-3'-adenylate and *all-P-ambo*-thymidylyl-(5'→3')-thymidylyl-(5'→3')-2'-*O*-methyl-*P*-thiouridylyl-(5'→3')-2'-*O*-methyl-*P*-thiouridylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methylcytidyl-(5'→3')-2'-deoxy-2'-fluoroguanlyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methylcytidyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-*O*-methyluridylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thiouridylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(5'→3')-2'-*O*-methyluridine

cemisiran



duplex de l'hydrogène-*tout-P-ambo*-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-*O*-méthyl-*P*-thioadénylyl-(3'→5')-2'-déoxy-2'-fluoroguanlyl-(3'→5')-2'-*O*-méthylcytidyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluoroguanlyl-(3'→5')-2'-*O*-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorouridylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluoroadénylyl-(3'→5')-2'-*O*-méthyluridylyl-(3'→5')-2'-*O*-méthyl-3'-adénylate de

**Legend**

X : 2'-deoxyx-2'-fluoro

X : 2'-O-methyl

Z : thymidine

**clivatuzumabum tetraxetanum #**
clivatuzumab tetraxetan

immunoglobulin G1-kappa, anti-[*Homo sapiens* MUC1 (mucin 1, polymorphic epithelial mucin, PEM, CD227)], humanized monoclonal antibody, tetraxetan conjugate; gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*03, G1m3 (CH1 (120-217), (hinge 218-232), CH2 (233-342), CH3 (343-447), CH-S (448-449)) (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; (228-228":231-231")-bisdisulfide dimer; tetraxetan (DOTA) conjugate (on an average of 4 to 7 lysyl, linked to the chelator by their N^{δ})

clivatuzumab tétraxétan

immunoglobuline G1-kappa, anti-[*Homo sapiens* MUC1 (mucine 1, mucine épithéliale polymorphique, PEM, CD227)], anticorps monoclonal humanisé, conjugué au tétraxétan; chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*03, G1m3 (CH1 (120-217), (hinge 218-232), CH2 (233-342), CH3 (343-447), CH-S (448-449)) (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimère (228-228":231-231")-bisdisulfure; conjugué au tétraxétan (DOTA) (avec une moyenne de 4 à 7 lysyl liés au chélateur par leur N^{δ})

clivatuzumab tetraxetán

immunoglobulina G1-kappa, anti-[*Homo sapiens* MUC1 (mucina 1, mucina epitelial polimórfica, PEM, CD227)], anticuerpo monoclonal humanizado, conjugado con tetraxetán;

cadena pesada gamma1 (1-449) [VH humanizado (*Homo sapiens* IGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) - *Homo sapiens* IGHG1*03, G1m3 (CH1 (120-217), (bisagra 218-232), CH2 (233-342), CH3 (343-447), CH-S (448-449)) (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizado (*Homo sapiens* IGKV1-13*02 (78.90%) -IGKJ2*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dímero (228-228":231-231")-bisdisulfuro; conjugado con tetraxetán (DOTA) (con una media de 4 a 7 restos lisil unidos al quelante por sus respectivos N⁶)

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQQSGAE VKKPGASVKV SCEASGYTFP SYVLHWVKQA PGQGLEWIGY 50
INPYNDGTQY NEKFKGKATL TRDTSINTAY MELSLRSGDD TAVYYCARGF 100
GGSYGFAYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TTPAVLQSSG LYSLSVVTV PSSSLGTQTY 200
ICNVNHKPSN TKVDKRVPEK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPV 400
DSDGSFFLYS KLTVDKSRWQ QGNVFCSCVM HEALHNHYTQ KSLSLSPGK 449

Light chain / Chaîne légère / Cadena ligera

DIQLTQSPSS LSASVGRVMT MTCASSSVS SSYLYWYQK PGKAPKLWIY 50
STSNLASGVP ARFSGSGSGT DFTLTISLQ PEDSASYFCH QWNRYPYTFG 100
GGTRLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YPREAKVQWK 150
VDNALQSGNS QESVTEQDSK DSTYLSSTL TSKADYERK KVIACEVTHQ 200
GLSPFTKSF NRGEC 215

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 146-202 263-323 369-427
22"-96" 146"-202" 263"-323" 369"-427"
Intra-L (C23-C104) 23"-89" 135"-195"
23"-89" 135"-195"
Inter-H-L (h 5-CL 126) 222-215' 222"-215"
Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

299, 299"

Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires complexes fucosylés / glicanos de tipo Sp2/0 biantenarijos complejos fucosilados


Modified residues / Résidus modifiés / Restos modificados

4 to 7 lysyl (K)

4 à 7 lysyl (K)

4 a 7 lisil (K)

N⁶-(tetraxetan)-L-lysyl



crotedumabum #
crotedumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* GCGR (glucagon receptor)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain (1-455) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD)-IGHJ6*01) [8.8.21] (1-128) - IGHG4*01 (CH1 (129-226), hinge S10>P (236) (227-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (129-455)], (142-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-17*01 (95.80%) - IGKJ3*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214'))]; dimer (234-234":237-237")-bisdisulfide

crotédumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* GCGR (récepteur du glucagon)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma4 (1-455) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD) -IGHJ6*01) [8.8.21] (1-128) -IGHG4*01 (CH1 (129-226), charnière S10>P (236) (227-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (129-455)], (142-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214'))]; dimère (234-234":237-237")-bisdisulfure

crotedumab

immunoglobulina G4-kappa, anti-[*Homo sapiens* GCGR (receptor de glucagón)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma4 (1-455) [*Homo sapiens* VH (IGHV3-7*01 (92.90%) -(IGHD) -IGHJ6*01) [8.8.21] (1-128) -IGHG4*01 (CH1 (129-226), bisagra S10>P (236) (227-238), CH2 (239-348), CH3 (349-453), CHS (454-455)) (129-455)], (142-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ3*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214'))]; dímero (234-234":237-237")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGFTFS NYLMNWVRQA PGKGLEWLAN 50
IQEDGIEKYY VDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREP 100
SHYDILTGYD YYYGMDVWGQ GTTIVTVSSAS TKGPSVFPLA PCSRSTSEST 150
AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP 200
SSSLGTKTYT CNVDHKFSNT KVDKRVESKY GPCCPFCFAP EFLGGPSPVFL 250
FPPKPKDTLM ISRTPEVTCV VVDVVSQEDPE VQFNWYVDGV EVHNAKTKPR 300
EEQFNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKGLPSSI EKTISKAKGQ 350
PREPQVYTLF PSQEEEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK 400
TTPPVLDSDG SFFFLYSRLTV DKSRWQEGNV FSCSVMEAL HNHYTQKSL 450
LSLGK 455
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRVIT ITCRASQGIT NDLGWYQQKP GKAPKRLIYA 50
ASSLSQGVPS RFGSGSGSTE FILTVSSLQF EDFATYYCLQ YNSNPFTFGP 100
GTRVDIKRTV AAPSVFIFFP SDEQLKSGTA SVVCLLNIFY BREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	155-211	269-329	375-433
	22"-96"	155"-211"	269"-329"	375"-433"
Intra-L (C23-C104)	23'-88"	134'-194"		
	23'''-88'''	134'''-194'''		
Inter-H-L (CH1 10-CL 126)	142-214'	142"-214'"		
Inter-H-H (h 8, h 11)	234-234"	237-237"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

305, 305"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

dapansutrilum

dapansutríle



3-(methanesulfonyl)propanenitrile

dapansutríle

3-(méthanesulfonyl)propanenitrile

dapansutrílo

3-(metanosulfonyl)propanonitrilo

**deudextromethorphanum**



deudextromethorphan

3-[(²H₃)methoxy]-17-[(²H₃)methyl]-*ent*-morphinan

deudextromethorpane

3-[(²H₃)méthoxy]-17-[(²H₃)méthyl]-*ent*-morphinane

deudextrometorfanò

3-[(²H₃)metoxi]-17-[(²H₃)metil]-*ent*-morfinano**dociparstatum natricum**

dociparstat sodium


sodium salt of 2,3-di-O-desulfoheparin, the starting material is an unfractionated heparin from porcine intestinal mucosa, the relative average molecular mass is approximately 12,000 daltons with about 40% ranging between 8,000 and 16,000 daltons, the degree of sulfation is about 2.0 per disaccharidic unit

dociparstat sodique

sel de sodium de la 2,3-di-O-désulfohéparine, obtenu à partir d'héparine non-fractionnée de la muqueuse intestinale porcine; sa masse moléculaire relative dont environ 40% est comprise entre 8.000 et 16.000 daltons, est voisine de 12.000 daltons; son degré de sulfatation est d'environ 2,0 par unité disaccharide

dociparstat sodico

sal de sodio de la 2,3-di-O-desulfoheparina, obtenida a partir de la heparina no fraccionad de la mucosa intestinal porcina; la masa molecular relativa media es aproximadamente de 12000 daltons con el 40% comprendido entre 8000 y 16000 daltons; el grado de sulfatación es de 2,0 por unidad de disacárido.



dolcanatidum

dolcanatide



1D, 16D-[3-L-glutamic acid]human uroguanylin:
 S^4, S^{12}, S^7, S^{15} -dicyclo(D-asparaginyl-L- α -aspartyl-
 L- α -glutamyl-L-cysteinyl-L- α -glut-amil-L-leucyl-L-cysteinyl-
 L-valyl-L-asparaginyl-L-valyl-L-alanyl-L-cysteinyl-
 L-threonylglycyl-L-cysteinyl-L-leucine)

dolcanatide

1D, 16D-[3-acide L-glutamique]uroguanyline humaine:
 S^4, S^{12}, S^7, S^{15} , dicyclo(D-asparaginyL-L- α -aspartyl
 -L- α -glutamyl-L-cystéinyl-L- α -glut-amyL-L-leucyl-L-cystéinyl-
 L-valyl-L-asparaginyL-L-valyl-L-alanyl-L-cystéinyl-
 L-thréonylqlvcyl-L-cystéinyl-D-leucine)

dolcanatida

1D,16D-[3-L-ácido glutámico]uroguanilina humana:
S⁴,S¹²,S⁷,S¹⁵-diciclo(D-asparaginil-L-α-aspartil-L-α-glutamil-
L-cisteinil-L-α-glut-amil-L-leucil-L-cisteinil-L-valil-
L-asparaginil-L-valil-L-alanil-L-cisteinil-L-treonilglicil-
L-cisteinil-D-leucina)



domagrozumabum

domagrozumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MSTN (growth differentiation factor 8, GDF8, myostatin, GDF-8)], humanized monoclonal antibody; gamma1 heavy chain (1-446) [humanized VH (*Homo sapiens* IGHV3-23*03 (94.90%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG1*01 (CH1 (117-214), hinge (215-229), CH2 L1.3>A (233), L1.2>A (234), G1>A (236) (230-339), CH3 D12>E (355), L14>M (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (225-225":228-228")-disulfide

domagrozumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MSTN (facteur de croissance et de différenciation 8, GDF8, myostatine, GDF-8)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-446) [VH humanisé (*Homo sapiens* IGHV3-23*03 (94.90%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG1*01, G1m17.1 (CH1 (117-214), charnière (215-229), CH2 L1.3>A (233), L1.2>A (234), G1>A (236) (230-339), CH3 D12>E (355), L14>M (357) (340-444), CHS (445-446)) (117-446)], (219-214)* disulfure avec la chaîne légère (1'-214')] [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (225'-225':228-228')-bisdisulfure

domagrozumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MSTN (factor de crecimiento y de diferenciación 8, GDF8, miostatina, GDF-8)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-446) [VH humanizado (*Homo sapiens* IGHV3-23*03 (94.90%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG1*01 (CH1 (117-214), bisagra (215-229), CH2 L1.3>A (233), L1.2>A (234), G1>A (236) (230-339), CH3 D12>E (355), L14>M (357) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (225-225'':228-228'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESQGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVST 50
ISSGGSYTSY PDSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAKQD 100
YAMNYWGQGT LVTSSASTK GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSQGVHTFP AVLQSSGLYS LSSVTVTPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PEAAGAPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY KTTTPVLDS 400
GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGRVIT ITCKASQDVS TAVAWYQQKP GKAPKLLIYS 50
ASYRYTGVPF RFGSGSGSDT FTLTISSLQP EDFATYCCQQ HYSTPWTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGEK 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 143-199 260-320 366-424
 22"-96" 143"-199" 260"-320" 366"-424"
 Intra-L (C23-C104) 23-88" 134-194"
 23"-88" 134"-194"
 Inter-H-L (h 5-CL 126) 219-214' 219"-214"
 Inter-H-H (h 11, h 14) 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

296, 296"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires

complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

Other post-translational modifications / Autres modifications post-traductionnelles / Otras

modificaciones post-traduccionales

C-terminal trimming of the C-terminal lysine (K)

H CHS K2:

446, 446"

edasalonexentum

edasalonexent

N-{2-[(4*Z*,7*Z*,10*Z*,13*Z*,16*Z*,19*Z*)-docosa-4,7,10,13,16,19-hexaenamido]ethyl}-2-hydroxybenzamide


édasalonexent

N-{2-[(4*Z*,7*Z*,10*Z*,13*Z*,16*Z*,19*Z*)-docosa-4,7,10,13,16,19-hexaénamido]éthyl}-2-hydroxybenzamide

edasalonexento

N-{2-[(4*Z*,7*Z*,10*Z*,13*Z*,16*Z*,19*Z*)-docosa-4,7,10,13,16,19-hexaenamido]etil}-2-hidroxibenzamida

C₂₈H₃₉N₃O₂



edonerpicum

edonerpic


1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}azetidin-3-ol

édonerpic

1-{3-[2-(1-benzothiophén-5-yl)éthoxy]propyl}azétidin-3-ol

edonerpico

1-{3-[2-(1-benzotiofen-5-il)etoxi]propil}azetidin-3-ol

 $C_{16}H_{21}NO_2S$ **enoblituzumabum #**

enoblituzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], humanized monoclonal antibody; gamma1 heavy chain (1-452) [humanized VH (*Homo sapiens* IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03 (CH1 (123-220), hinge (221-235), CH2 L1.2>V (240), F7>L (248), R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401) (346-450), CHS (451-452)) (123-452)], (225-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1D-13*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214'))]; dimer (231-231":234-234")-bisdisulfide

énoblituzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-452) [VH humanisé (*Homo sapiens* IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03 (CH1 (123-220), charnière (221-235), CH2 L1.2>V (240), F7>L (248), R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401) (346-450), CHS (451-452)) (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1D-13*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214'))]; dimère (231-231":234-234")-bisdisulfure

enoblituzumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* CD276 (B7H3, B7-H3, B7RP-2)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-452) [VH humanizado (*Homo sapiens* IGHV3-48*02 (91.80%) -(IGHD) -IGHJ6*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*03 (CH1 (123-220), bisagra (221-235), CH2 L1.2>V (240), F7>L (248), R83>P (297), Y85.2>L (305) (236-345), CH3 P83>L (401) (346-450), CHS (451-452)) (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1D-13*01 (85.10%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214'))]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVELVESGGG LVQPGGSLRL SCAASGFTFT SYWMSWVRQA PGKGLELVSS 50
 ITSYGSTFTY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARNM 100
 YTHFDSWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVTVPS SSLGTQTYIC 200
 NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT 250
 LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT 350
 LPFSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLDS 400
 DGSFFLYSKL TVDKSRWQQG NVFSCSVMEH ALHNHYTQKS LSLSPGK 447

Light chain / Chaîne légère / Cadena ligera

DIVLTQPPSV SGAPGQRVTI SCSGSSSNIG SNSVSYQQQL PGTAPKLLIY 50
 DNSKRPSGVP DRFSGSKSGT SASLAITGLQ SEDEADYCYC SRDTYGYWV 100
 FGGGKTLTVL GQPKAAPSVT LFPSSSEELQ ANKATLVCLI SDFYPGAVTV 150
 AWKGDSSPVK AGVETTPPSK QSNNKYAASS YLSLTPEQWK SHRSYSCQVT 200
 HEGSTVEKTV APTECS 216

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 144-200 261-321 367-425
 22"-96" 144"-200" 261"-321" 367"-425"
 Intra-L (C23-C104) 22'-89' 138'-197'
 22'"-89'" 138'"-197'"
 Inter-H-L (h 5-CL 126) 220-215' 220"-215"
 Inter-H-H (h 11, h 14) 226-226' 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

297, 297"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

epacadostatum

epacadostat

(Z)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-
 4-[[2-(sulfamoylamino)ethyl]amino]-1,2,5-oxadiazole-
 3-carboximidamide


épacadostat

(Z)-N-(3-bromo-4-fluorophényl)-N'-hydroxy-
 4-[[2-(sulfamoylamino)éthyl]amino]-1,2,5-oxadiazole-
 3-carboximidamide

epacadostat

(Z)-N-(3-bromo-4-fluorofenil)-N'-hidroxi-
 4-[[2-(sulfamoylamino)etil]amino]-1,2,5-oxadiazol-
 3-carboximidamida

C₁₁H₁₃BrFN₇O₄S

**esaxerenonum**

esaxerenone



(5*P*)-1-(2-hydroxyethyl)-N-[4-(methanesulfonyl)phenyl]-
 4-methyl-5-[2-(trifluoromethyl)phenyl]-1*H*-pyrrole-
 3-carboxamide

ésaxérénone

(5*P*)-1-(2-hydroxyéthyl)-N-[4-(méthanesulfonyl)phényl]-
 4-méthyl-5-[2-(trifluorométhyl)phényl]-1*H*-pyrrole-
 3-carboxamide

esaxerenona

(5*P*)-1-(2-hidroxietyl)-N-[4-(metanosulfonyl)fenil]-4-metil-
 5-[2-(trifluorometil)fenil]-1*H*-pirrol-3-carboxamida



fexapotidum

fexapotide


L-isoleucyl-L- α -aspartyl-L-glutamyl-L-glutamyl-L-valyl-L-leucyl-L-seryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L- α -glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cysteinyl-L-leucine

fexapotide

L-isoleucyl-L- α -aspartyl-L-glutamyl-L-glutamyl-L-valyl-L-leucyl-L-séryl-L-arginyl-L-isoleucyl-L-lysyl-L-leucyl-L- α -glutamyl-L-isoleucyl-L-lysyl-L-arginyl-L-cystéinyl-L-leucine

fexapotida

L-isoleucil-L- α -aspartil-L-glutaminil-L-glutaminil-L-valil-
L-leucil-L-seril-L-arginil-L-isoleucil-L-lisil-L-leucil-L- α -glutamil-
L-isoleucil-L-lisil-L-arginil-L-cisteinil-L-leucina



flortaucipirum (^{18}F)

flortaucipir (^{18}F)



7-[6-(¹⁸F)fluoropyridin-3-yl]-5*H*-pyrido[4,3-*b*]indole

flortaucipir (^{18}F)

7-[6-(¹⁸F)fluoropyridin-3-yl]-5*H*-pyrido[4,3-*b*]indole

flortaucipir (^{18}F)

7-[6-(¹⁸F)fluoropiridin-3-il]-5*H*-pirido[4,3-*b*]indol



fonadelparum

fonadelpar


{[5-methyl-3-(2-{4-(propan-2-yl)-
2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}ethyl)-
1,2-benzoxazol-6-yl]oxy}acetic acid

fonadelpar

acide {[5-méthyl-3-(2-{4-(propan-2-yl)-
2-[4-(trifluorométhyl)phényl]-1,3-thiazol-5-yl}éthyl)-
1,2-benzoxazol-6-yl]oxy}acétique

fonadelpar

ácido {[5-metil-3-(2-{4-(propan-2-il)-
2-[4-(trifluorometil)fenil]-1,3-tiazol-5-il}etil)-1,2-benzoxazol-
6-il]oxi}acético

C₂₅H₂₃F₃N₂O₄S

galcanezumabum #
galcanezumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* CALCA (calcitonin-related polypeptide alpha, calcitonin 1, CALC1) and *Homo sapiens* CALCB (calcitonin-related polypeptide beta, calcitonin 2, CALC2)], humanized monoclonal antibody;
gamma4 heavy chain (1-445) [humanized VH (*Homo sapiens* IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01) [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), hinge S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214'')]; dimer (225-225'':228-228'')-bisdisulfide

galcanézumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* CALCA (polypeptide alpha apparenté à la calcitonine, calcitonine 1, CALC1) et *Homo sapiens* CALCB (polypeptide beta apparenté à la calcitonine, calcitonine 2, CALC2)], anticorps monoclonal humanisé;
chaîne lourde gamma4 (1-445) [VH humanisé (*Homo sapiens* IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01) [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), charnière S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214'')]; dimère (225-225'':228-228'') bisdisulfure

galcanezumab

immunoglobulina G4-kappa, anti-[*Homo sapiens* CALCA (polipéptido alfa relacionado con la calcitonina, calcitonina 1, CALC1) y *Homo sapiens* CALCB (polipéptido beta relacionado con la calcitonina, calcitonina 2, CALC2)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-445) [VH humanizado (*Homo sapiens* IGHV1-69*01 (82.70%) -(IGHD) -IGHJ6*01) [8.8.12] (1-119)), IGHG4*01 (CH1 (120-217), bisagra S10>P (227)(218-229), CH2 F1.3>A (233), L1.2>A (234) (230-339), CH3 (340-444), CHS K2>del (445)) (120-445)], (133-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214'')]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VKKPGSSVKV SKKASGYTFG NYWMQWVRQA PGQGLEWMGA 50
IYEGTGKTVY IQKFADRVTI TADKSTSTAY MELSSLRSED TAVYYCARLS 100
DYVSGFGYWG QGTTVTVSSA STKGFSVFPL APCSRSTSES TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TFPVQLQSSG LYSLSVVTV PSSSLGKTLY 200
TCNVDPKPSN TKVDKRVESK YGPPCPPCA PEAAGGPSVF LFPPKPKDTL 250
MISRTPEVTC VVVDVQEDP EVQFNWYVDG VEVHNAKTKP REEQFNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNGKLPSL IEKTISKAKG QPREPQVYTL 350
PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTTPVLDSD 400
GSFFLYSRLT VDKSRWQEGN VFSCSVMEHA LHNHYTQKSL SLSLG 445
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGRVT ITCRASKDIS KYLNWYQQKFP GKAPKLLIYY 50
TSGYHSGVPS RFGSGSGGTD FTLTISSLQP EDFATYYCQG GDALPPTFGG 100
GTRVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSSSTLT LSKADYEKHK VYACEVTHQG 200
LSPFVTKSFN RGECC 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 146-202 260-320 366-424
 22"-96" 146"-202" 260"-320" 366"-424"
 Intra-L (C23-C104) 23'-88' 134'-194'
 23'''-88''' 134'''-194'''
 Inter-H-L (CH1 10-CL 126) 133-214' 133"-214"
 Inter-H-H (h 8, h 11) 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 296, 296"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

galidesivirum

galidesivir



(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol

galidésivir

(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxyméthyl)pyrrolidine-3,4-diol

galidesivir

(2S,3S,4R,5R)-2-(4-amino-5H-pirrololo[3,2-d]pirimidin-7-il)-5-(hidroximetil)pirrolidina-3,4-diol



givosiranum

givosiran

duplex of [(2*S*,4*R*)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis[{3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl]-4-hydroxypyrrolidin-2-yl]methyl hydrogen *all-P-ambo*-2'-O-methyl-*P*-thiocytidylyl-(3'→5')-2'-O-methyl-*P*-thioadenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanlylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-fluoroguanlylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluoroguanlylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyl-3'-adenylate and *all-P-ambo*-2'-O-methyl-*P*-thiouridylyl-(5'→3')-2'-O-methyl-*P*-thioguanlylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluoroguanlylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(5'→3')-2'-deoxy-2'-fluoro-*P*-thioadenylyl-(5'→3')-2'-O-methyluridine



givosiran

duplex de l'hydrogène-*tout-P-ambo*-2'-O-méthyl-*P*-thiocytidylyl-(3'→5')-2'-O-méthyl-*P*-thioadénylyl-(3'→5')-2'-O-méthylguanylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluoroguanlylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-déoxy-2'-fluoroguanlylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluoroguanlylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-déoxy-2'-fluorocytidylyl-(3'→5')-2'-O-méthyladénylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthylcytidylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthyluridylyl-(3'→5')-2'-O-méthyl-3'-adénylate de [(2*S*,4*R*)-1-{1-[(2-acétamido-2-déoxy-β-D-galactopyranosyl)oxy]-16,16-bis[{3-[(3-{5-[(2-acétamido-2-déoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}méthyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl]-4-hydroxypyrrolidin-2-yl]méthyle et

givosirán

du *tout-P-ambo-2'-O-méthyl-P-thiouridylyl-(5'→3')-2'-O-méthyl-P-thioguanilyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthylcytidilyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthyluridylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthylcytidilyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthylcytidilyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluoroadénylyl-(5'→3')-2'-O-méthylguanylyl-(5'→3')-2'-déoxy-2'-fluorouridylyl-(5'→3')-2'-O-méthyladénylyl-(5'→3')-2'-déoxy-2'-fluoroguanilyl-(5'→3')-2'-déoxy-2'-fluoro-*P*-thioadénylyl-(5'→3')-2'-déoxy-2'-fluoro-*P*-thioadénylyl-(5'→3')-2'-O-méthyluridine*


dúplex del hidrógeno-*todo-P-ambo-2'-O-metil-P-tiocitidilil-(3'→5')-2'-O-metil-P-tioadenilil-(3'→5')-2'-O-metilguanilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluoroguanilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-desoxi-2'-fluorocitidilil-(3'→5')-2'-O-metiladenilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metilcitidilil-(3'→5')-2'-O-metiluridilil-(3'→5')-2'-O-metil-3'-adenilato de [(2*S*,4*R*)-1-{1-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]-16,16-bis({3-{3-{5-[(2-acetamido-2-desoxi-β-D-galactopiranosil)oxi]pentanamido}propil)amino}-3-oxopropoxi)metil)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-ol}-4-hidroxipirrolidin-2-il]metilo y del *todo-P-ambo-2'-O-metil-P-tiouridilil-(5'→3')-2'-O-metil-P-tioguanilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-metiluridilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O-metilcitidilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi-2'-fluoroadenilil-(5'→3')-2'-O-metilguanilil-(5'→3')-2'-desoxi-2'-fluorouridilil-(5'→3')-2'-O-metiladenilil-(5'→3')-2'-desoxi-2'-fluoroguanilil-(5'→3')-2'-desoxi-2'-fluoro-*P*-tioadenilil-(5'→3')-2'-O-metiluridina**



Legend

X : 2'-deoxy-2'-fluoro

X : 2'-O-methyl



glecaprevirum

glecaprevir


(3a*R*,7*S*,10*S*,12*R*,21*E*,24a*R*)-7-*tert*-butyl-*N*-{[(1*R*,2*R*)-2-(difluoromethyl)-1-[(1-methylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodecahydro-1*H*,10*H*-9,12-methanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadecino[11,12-*b*]quinoxaline-10-carboxamide

glécaprévir

(3a*R*,7*S*,10*S*,12*R*,21*E*,24a*R*)-7-*tert*-butyl-*N*-{[(1*R*,2*R*)-2-(difluorométhyl)-1-[(1-méthylcyclopropane-1-sulfonyl)carbamoyl]cyclopropyl]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodécahydro-1*H*,10*H*-9,12-méthanocyclopenta[18,19][1,10,17,3,6]trioxadiazacyclononadécino[11,12-*b*]quinoxaline-10-carboxamide

glecaprevir

(3a*R*,7*S*,10*S*,12*R*,21*E*,24a*R*)-7-*tert*-butil-*N*-{[(1*R*,2*R*)-2-(difluorometil)-1-[(1-metilciclopropano-1-sulfonyl)carbamoyl]ciclopropil]-20,20-difluoro-5,8-dioxo-2,3,3a,5,6,7,8,11,12,20,23,24a-dodécahidro-1*H*,10*H*-9,12-metanociclopenta[18,19][1,10,17,3,6]trioxadiazaciclonoñadecino[11,12-*b*]quinoxalina-10-carboxamida

C₃₈H₄₆F₄N₆O₉S**glesatinibum**

glesatinib



N-[(3-fluoro-4-[[2-(5-[(2-methoxyethyl)amino]methyl)pyridin-2-yl]thieno[3,2-*b*]pyridin-7-yl]oxy)phenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide

glésatinib

N-[(3-fluoro-4-[[2-(5-[(2-méthoxyéthyl)amino]méthyl)pyridin-2-yl]thiéno[3,2-*b*]pyridin-7-yl]oxy}phényl)carbamothioyl]-2-(4-fluorophényl)acétamide

glesatinib

N-[(3-fluoro-4-[[2-(5-[(2-metoxietil)amino]metil]piridin-2-il]tieno[3,2-*b*]piridin-7-il]oxi}fenil)carbamotioil]-2-(4-fluorofenil)acetamida


**inclisiranum**

inclisiran

duplex of [(2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis[{3-[(3-[5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamide)propyl]amino}-3-oxopropoxy)methyl]-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl)methyl hydrogen *all-P-ambo*-2'-O-methyl-*P*-thiocytidyl(3'→5')-2'-O-methyl-*P*-thiouridyl(3'→5')-2'-O-methyladenyl(3'→5')-2'-O-methylguanylyl(3'→5')-2'-O-methyladenyl(3'→5')-2'-O-methylcytidyl(3'→5')-2'-deoxy-2'-fluorocytidyl(3'→5')-2'-O-methyluridyl(3'→5')-2'-deoxy-2'-fluoroguanlyl(3'→5')-2'-O-methyluridyl(3'→5')-thymidyl(3'→5')-2'-O-methyluridyl(3'→5')-2'-O-methyluridyl(3'→5')-2'-O-methylguanylyl(3'→5')-2'-O-methylcytidyl(3'→5')-2'-O-methyluridyl(3'→5')-2'-O-methyluridyl(3'→5')-2'-O-methyluridyl(3'→5')-2'-O-methyluridyl(3'→5')-2'-O-methyluridyl(3'→5')-2'-O-methylguanylyl(3'→5')-2'-O-methyl-3'-uridylate and *all-P-ambo*-2'-O-methyl-*P*-thioadenyl(5'→3')-2'-O-methyl-*P*-thioadenyl(5'→3')-2'-O-methylguanylyl(5'→3')-2'-O-methyladenyl(5'→3')-2'-O-methyluridyl(5'→3')-2'-deoxy-2'-fluorocytidyl(5'→3')-2'-O-methyluridyl(5'→3')-2'-deoxy-2'-fluoroguanlyl(5'→3')-2'-O-methylguanylyl(5'→3')-2'-deoxy-2'-fluoroadenyl(5'→3')-2'-O-methylcytidyl(5'→3')-2'-deoxy-2'-fluoroadenyl(5'→3')-2'-O-methyladenyl(5'→3')-2'-deoxy-2'-fluoroadenyl(5'→3')-2'-O-methyladenyl(5'→3')-2'-deoxy-2'-fluorocytidyl(5'→3')-2'-O-methylguanylyl(5'→3')-2'-deoxy-2'-fluoroadenyl(5'→3')-2'-deoxy-2'-fluoroadenyl(5'→3')-2'-deoxy-2'-fluoroadenyl(5'→3')-2'-O-methyl-*P*-thioadenyl(5'→3')-2'-deoxy-2'-fluoro-*P*-thiocytidyl(3'→3')-2'-O-methyladenosine

inclisiran

duplex de l'hydrogéné-*tout-P-ambo-2'-O-méthyl-*
P-thiocytidyl-(3'→5')-2'-*O*-méthyl-*P*-thiouridyl-(3'→5')-
 2'-*O*-méthyladényl-(3'→5')-2'-*O*-méthylguanyl-(3'→5')-
 2'-*O*-méthyladényl-(3'→5')-2'-*O*-méthylcytidyl-(3'→5')-
 2'-déoxy-2'-fluorocytidyl-(3'→5')-2'-*O*-méthyluridyl-(
 3'→5')-2'-déoxy-2'-fluoroguanyl-(3'→5')-2'-*O*-
 méthyluridyl-(3'→5')-thymidyl-(3'→5')-2'-*O*-
 méthyluridyl-(3'→5')-2'-*O*-méthyluridyl-(3'→5')-2'-*O*-
 méthylguanyl-(3'→5')-2'-*O*-méthylcytidyl-(3'→5')-2'-*O*-
 méthyluridyl-(3'→5')-2'-*O*-méthyluridyl-(3'→5')-2'-*O*-
 méthyluridyl-(3'→5')-2'-*O*-méthyluridyl-(3'→5')-2'-*O*-
 méthylguanyl-(3'→5')-2'-*O*-méthyl-3'-uridylate de

**intepirdinum**

intepirdine


intépirdine

intepirdina

3-(benzenesulfonyl)-8-(piperazin-1-yl)quinolone

3-(benzènesulfonyl)-8-(pipérazin-1-yl)quinolone


3-(bencenosulfonil)-8-(piperazin-1-il)quinolina

 $\text{C}_{19}\text{H}_{19}\text{N}_3\text{O}_2\text{S}$ **ivosidenibum**

ivosidenib

ivosidénib

ivosidenib

(2*S*)-*N*-{(1*S*)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-*N*-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide(2*S*)-*N*-{(1*S*)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-*N*-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide(2*S*)-*N*-{(1*S*)-1-(2-clorofenil)-2-[(3,3-difluorociclobutil)amino]-2-oxoetil}-1-(4-cianopiridin-2-il)-*N*-(5-fluoropiridin-3-il)-5-oxopirrolidina-2-carboxamida $\text{C}_{28}\text{H}_{22}\text{ClF}_3\text{N}_6\text{O}_3$ 

lanadelumabum #

lanadelumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* KLKB1 (kallikrein B 1, plasma prekallikrein (zymogen), kininogenin, Fletcher factor) proteolytically cleaved by F12 (factor FXII), active plasma kallikrein (EC 3.4.21.34)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1-122) -IGHG1*03, G1m3 (CH1 (123-220), hinge (221-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451))(123-451)], (225-213')-disulfide with kappa light chain (1'-213') [*Homo sapiens* V-KAPPA (IGKV1-5*03 (97.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')]; dimer (231-231'':234-234'')-bisdisulfide

lanadélumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* KLKB1 (kallikréine B 1, prékallikréine plasmatique (zymogène), kininogénine, facteur de Fletcher) clivé protéolytiquement par F12 (facteur FXII), kallikréine plasmatique active (EC 3.4.21.34)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1-122) -IGHG1*03, G1m3 (CH1 (123-220), charnière (221-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (123-451)], (225-213')-disulfure avec la chaîne légère kappa (1'-213') [*Homo sapiens* V-KAPPA (IGKV1-5*03 (97.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')]; dimère (231-231'':234-234'')-bisdisulfure

lanadelumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* KLKB1 (kalikreína B 1, prekalikreína plasmática (zimógeno), kininogenina, factor de Fletcher) dividida proteolíticamente por F12 (factor FXII), kalikreína plasmática activa (EC 3.4.21.34)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*03 (91.80%) -(IGHD) -IGHJ3*02) [8.8.15] (1-122) -IGHG1*03, G1m3 (CH1 (123-220), bisagra (221-235), CH2 (236-345), CH3 (346-450), CHS K2>del (451)) (123-451)], (225-213')-disulfuro con la cadena ligera kappa (1'-213') [*Homo sapiens* V-KAPPA (IGKV1-5*03 (97.90%) -IGKJ1*01) [6.3.8] (1'-106') -IGKC*01, Km3(107'-213')]; dímeo (231-231'':234-234'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLLESGGG LVQPGGSLRL SCAASGTFIS HYIMMWVRQA PGKLEWVSG 50
 IYSSGGITVY ADSVKGRFTI SRDNSKNTLY LQMNLSRAED TAVYYCAYRR 100
 IGVPFRDEFD IWGQGTMTV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
 VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SGLYSLSSV VTPSSSLGT 200
 QTYICNVNHH PSNTKVDKRV EPKSCDKTHT CPPCPAPELL GGPVSFLFPP 250
 KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ 300
 YNSTYRVSVS LTVLHQDWLN GKEYKCKVSN KALPAIEKT ISKAKQPRE 350
 PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTT 400
 PVLDSGDSGFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNN YTQKSLSLSP 450
 G 451

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPST LSASVGDRVT ITCRASQIS SWLAWYQQKPK GKAPKLLIYK 50
 ASTLESGVPS RFGSGSGSTE FTLTISSLQP DDFATYYCQQ YNTYWTFGQG 100
 TKVEIKRTVA APSVFIFFPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
 NALQSGNSQE SVTEQDSKDS TYSLSSTLTSL SKADYEKHKV YACEVTHQGL 200
 SSPVTKSFNR GEC 213

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 149-205 266-326 372-430
 22"-96" 149"-205" 266"-326" 372"-430"
 Intra-L (C23-C104) 23"-88" 133'-193"
 23"-88" 133"-193"
 Inter-H-L (h 5-CL 126) 225-213' 225"-213"
 Inter-H-H (h 11, h 14) 231-231" 234-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

302, 302"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

laprituximabum

laprituximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], chimeric monoclonal antibody;

gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01 -IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (228-228":231-231")-bisdisulfide

laprituximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD) -IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01 - IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (228-228":231-231")-bisdisulfure.

laprituximab

immunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal quimérico;

cadena pesada gamma1 (1-448) [*Mus musculus* VH (IGHV1-7*01)-(IGHD)-IGHJ4*01] [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), bisagra (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448)) (120-448)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01 - IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VAKPGASVKL SCRASGYTFT SYWMQWVKQR PGQGLECIQT 50
IYPGDGDTTY TQKFQGKATL TADKSSSTAY MQLSSLSRSED SAVYYCARYD 100
APGYAMDYWG QGTLVTVSSA STKGPSVFPFL APSSKSTSGG TAALGCLVKD 150
YFPEPVTYVSW NSGALTSGVH TTPAVLQSSG LYSLSVVTV PSSSLGTQTY 200
ICNVNHHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250
DTLMISRTPE VTCVVDVSH EDPEVKFNWY VDGVEVHNK TKPREEQYNS 300
TYRVVSVLTV LHQDVLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPEVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSFG 448

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGRVT ITCRASQDIN NYLAWYQHQP GKGPCLLIHY 50
TSTLHPGIPS RFGSGSGGRD YSFSSISLEP EDIATYYCLQ YDNLLYTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY BREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKHK YVACEVTHQG 200
LSSEVTKSFN RGEQ 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23"-88"	134"-194"		
Inter-H-L (h 5-CL 126)	222-214'	222"-214"		
Inter-H-H (h 11, h 14)	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

laprituximabum emtansinum #
laprituximab emtansine

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], chimeric monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-448) [*Mus musculus* VH (IGHV1-7*01)-(IGHD)-IGHJ4*01] [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), hinge (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448) (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01-IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (228-228":231-231")-bisdisulfide; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker forming a nonreducible thioether bond

For the emtansine part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others".

laprituximab emtansine

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (Récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal chimérique conjugué au maytansinoïde DM1;

laprituximab emtansina

chaîne lourde gamma1 (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), charnière (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448) (120-448)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01-IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (228-228'':231-231'')-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maitansinoïde DM1 via un linker succinimidyl-4-(*N*-maléimidométhyl) cyclohexane-1-carboxylate (SMCC) formant une liaison thioéther non réductible

Pour la partie *emtansine*, veuillez-vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others".

immunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal quimérico conjugado con el maitansinoide DM1;

cadena pesada gamma1 (1-448) [*Mus musculus* VH (IGHV1-7*01 -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (120-217), bisagra (218-232), CH2 (233-342), CH3 (343-447), CHS K2>del (448) (120-448)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV19-93*01-IGKJ2*03) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (228-228'':231-231'')-bisdisulfuro; conjugado, de 3 a 4 restos lisil por término medio, con el maitansinoide DM1 mediante el conector succinimidil-4-(*N*-maleimidometil) ciclohexano-1-carboxilato (SMCC) formando una unión tioéter no reducible

La fracción *emtansina* se pueden encontrar en el documento "INN for pharmaceutical substances: Names for radicals, groups and others".

Structure

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VAKPGASVKL SCKASGYTFT SYWMQWVKQR PGQGLECIGT 50
IYPGDDGDTTY TQKFQGKATL TADKSSSTAY MQLSSLRSED SAVYGCARYD 100
APGYAMDYWG QGTLVTVSSA STKGPSVFPPL APSSKSTSGG TAALGCLVKD 150
YFPEPVTVSW NSGALTSGVH TTPAVLQSSG LYSLSVVTV PSSSLGTQTY 200
ICNVNHPKPSN TKVDKKVPEK SCDKTHCTPP CPAPELLGPP SVFLFPPKPK 250
DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
TYRVVSVLTV LHQDNLNGKE YKCKVSNKAL PAPIETISK AKGQPREPQV 350
YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPEVL 400
DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPG 448
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGRVIT ITCRASQDIN NYLAWYQHKK GKGPKLIIHY 50
TSTLHPGIPS RFGSGSGGRD YSFSSISLEP EDIATYYCLQ YDNLITYFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLNNFY PREAKVQWNV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSLTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTIKSFN RGEK 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 146-202 263-323 369-427
22"-96" 146"-202" 263"-323" 369"-427"

Intra-L (C23-C104) 23'-88" 134'-194"
23'''-88''' 134'''-194'''

Inter-H-L (h 5-CL 126) 222-214' 222"-214"

Inter-H-H (h 11, h 14) 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

299, 299"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

An average of 3 to 4 lysyl being conjugated each to a drug linker / 3 à 4 lysylen moyenne sont conjugués à un linker-principe actif / Una media de 3 a 4 lisil están conjugadas a conectores-principio activo.

lenadogenum nolparvovecum #

lenadogene nolparvovec

a non-replicating single stranded DNA recombinant adeno-associated virus (rAAV) serotype 2 containing human wt MT-*ND4* cDNA that encodes NADH Dehydrogenase subunit 4, under the control of the cytomegalovirus immediate early (CMVie) promoter in an intron-containing expression cassette (beta globin intron, *HBB2*), flanked by the viral inverted terminal repeats from AAV2/2.

lénadogène nolparvovec

vecteur viral adéno-associé de sérotype 2 recombinant (rAAV) non-répliquant, avec un ADN monocaténaire contenant le gène wt MT-*ND4* codant pour la sous-unité 4 de la NADH déshydrogénase humaine, sous le contrôle d'un cytomégalovirus immédiat précoce dans un intron contenant la cassette d'expression (intron bêta-globine, *HBB2*), flanqué de répétitions inverses dérivées du virus adéno-associé de sérotype 2

lenadogén nolparvovec

vector viral adeno-asociado de serotipo 2 recombinante (rAAV) no replicativo, con un ADN monocatenario que contiene el gen wt MT-*ND4* que codifica para la subunidad 4 de la NADH deshidrogenasa humano, bajo el control de un promotor inmediato temprano del citomegalovirus en un intron que contiene el cassette de expresión (intron beta-globin, *HBB2*), flanqueado de repeticiones inversas derivadas del virus adeno-asociado del serotipo 2

leniolisibum

leniolisib


1-[(3*S*)-3-({6-[6-methoxy-5-(trifluoromethyl)pyrimidin-3-yl]-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one

léniolisib

1-[(3*S*)-3-({6-[6-méthoxy-5-(trifluorométhyl)pyrimidin-3-yl]-5,6,7,8-tétrahydropyrido[4,3-*d*]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one

leniolisib

1-[(3*S*)-3-({6-[6-metoxi-5-(trifluorometil)pirimidin-3-il]-5,6,7,8-tetrahidropirido[4,3-*d*]pirimidin-4-il}amino)pirrolidin-1-il]propan-1-ona

C₂₁H₂₅F₃N₆O₂**levoketoconazolum**


levoketoconazole

1-[4-[4-((2*S*,4*R*)-2-(2,4-dichlorophenyl)-2-[(1*H*-imidazol-1-yl)methyl]-1,3-dioxolan-4-yl)methoxy)phenyl]piperazin-1-yl]ethan-1-one

lévokétoconazole

1-{4-[4-({(2*S*,4*R*)-2-(2,4-dichlorophényl)-2-[(1*H*-imidazol-1-yl)méthyl]-1,3-dioxolan-4-yl)méthoxy]phényl]pipérazin-1-yl}éthan-1-one

levoketoconazol

1-{4-[4-({(2*S*,4*R*)-2-(2,4-diclorofenil)-2-[(1*H*-imidazol-1-il)metil]-1,3-dioxolan-4-il}metoxi)fenil]piperazin-1-il}etan-1-ona $C_{26}H_{28}Cl_2N_4O_4$ **lorlatinibum**


lorlatinib

(10*R*)-7-amino-12-fluoro-2,10,16-triméthyl-15-oxo-10,15,16,17-tétrahydro-2*H*-4,8-méthénopyrazolo[4,3-*h*][2,5,11]benzoxadiazacyclotétradécine-3-carbonitrile

lorlatinib

(10*R*)-7-amino-12-fluoro-2,10,16-triméthyl-15-oxo-10,15,16,17-tétrahydro-2*H*-4,8-méthénopyrazolo[4,3-*h*][2,5,11]benzoxadiazacyclotétradécine-3-carbonitrile

lorlatinib

(10*R*)-7-amino-12-fluoro-2,10,16-triméthyl-15-oxo-10,15,16,17-tétrahydro-2*H*-4,8-méthénopyrazolo[4,3-*h*][2,5,11]benzoxadiazacyclotétradécine-3-carbonitrile $C_{21}H_{19}FN_6O_2$ **lumateperonum**

lumateperone



1-(4-fluorophényl)-4-[(6*bR*,10*aS*)-3-méthyl-2,3,6*b*,9,10,10*a*-hexahydro-1*H*-pyrido[3',4':4,5]pyrrolo[1,2,3-*de*]quinoxalin-8(7*H*)-yl]butan-1-one

lumatéperone

1-(4-fluorophényl)-4-[(6*bR*,10*aS*)-3-méthyl-2,3,6*b*,9,10,10*a*-hexahydro-1*H*-pyrido[3',4':4,5]pyrrolo[1,2,3-*de*]quinoxalin-8(7*H*)-yl]-butan-1-one

lumateperona

1-(4-fluorofenil)-4-[(6*bR*,10*aS*)-3-metil-2,3,6*b*,9,10,10*a*-hexahidro-1*H*-pirido[3',4':4,5]pirrolo[1,2,3-*de*]quinoxalin-8(7*H*)-il]butan-1-ona



mesmulogenum ancovaccineum #
mesmulogene ancovaccinec

a non-replicating recombinant vaccinia virus, based on the Modified Vaccinia Virus Ankara (MVA) strain, carrying sequences coding for the expression of the human Mucine 1 (MUC1) antigen and human Interleukin 2 (IL2), under the control of pH5R and p7.5 vaccinia promoters, respectively.

mesmulogène ancovaccinec

vecteur viral recombinant non-répliquant de la vaccine, dérivé du virus de la vaccine modifié Ankara, contenant les séquences d'ADN codant pour l'expression de l'antigène de la Mucine 1 et de l'interleukine 2 humaine, sous le contrôle des promoteurs pH5R et p7.5, respectivement

mesmulogén ancovaccinec

vector viral recombinante no replicativo de la vacuna, derivado de la cepa del virus de la vacuna modificada Ankara, que contiene las secuencias del ADN que codifica para la expresión del antígeno de la Mucina 1 (MUC1) y de la interleukina 2 humana (IL2), bajo el control de los promotores vaccinia pH5R y p7.5, respectivamente

mipeginterferonum alfa-2b #
mipeginterferon alfa-2b

$N^{2.1}, N^{6.Lys}$ -oligo(N -{2-[ω -methoxypoly(oxyethylene)- α -yl]acetyl}- N -[α -methylpoly(oxyethylene)- ω -yl]glycyl)human interferon alpha-2b, with an average number of 5 substituted among 11 amino groups (one N -terminal and 10 lysine N^6), the protein part being produced in *Pichia pastoris* (*Komagataella pastoris*)
The relative molecular mass of the polyethylene glycol part can be indicated after the INN, for example: mipeginterferon alfa-2b (40 kDa)

mipèginterféron alfa-2b

$N^{2.1}, N^{6.Lys}$ -oligo(N -{2-[ω -méthoxypoly(oxyéthylène)- α -yl]acétyl}- N -[α -méthylpoly(oxyéthylène)- ω -yl]glycyl)interféron alpha-2b humain, une moyenne de 5 azotes parmi les 11 (un N -terminal et 10 lysines N^6) sont substitués, la partie protéique étant produite par *Pichia pastoris* (*Komagataella pastoris*)
La masse molaire de la partie polyéthylène glycol peut être indiquée après la DCI, par exemple: mipèginterféron alfa-2b (40 kDa)

mirvetuximab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* FOLR1 (receptor 1 de folato, receptor alfa de folato, FR-alpha, proteína del adulto que liga el folato, FBP, antígeno Mov18 asociado a tumores ováricos)], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-447) [*Mus musculus* VH (IGHV1-37*01 -(IGHD) -IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (119-216), bisagra (217-231), CH2 (232-341), CH3 (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfuro con la cadena ligera kappa (1'-218') [*Mus musculus* V-KAPPA (IGKV3-9*01 -IGKJ2*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVQSGAE VVKPGASVKI SKKASGYTFT GYFMNWKQSG PGQSLWIGR 50
IHPYDGDIFY NQKFQGGKATL TVDKSSNTAH MELLSLTSED FAVYYCTRYD 100
GSRAMDYWGQ GTTIVTVSSAS TKGPSVFLPA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSGVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
TLPPSRDELIT KNQVSLTCLV KGFYPSDIAV EWESNGQFEN NYKTTTPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG 447
```

Light chain / Chaîne légère / Cadena ligera

```
DIVLTQSPLE LAVSLGQPAI ISCKASQSVS FAGTSLMHVY HQKPGQQPRL 50
LIYRASNLAE GVPDRFSGSG SKTDFTLTIS PVEAEDAATY YCQSQREYPY 100
TFGGGTKELEI KRTVAAPSVF IFPPSDEQLK SGTASVVCCL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLK STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC 218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22"-96"	145"-201"	262"-322"	368"-426"
Intra-L (C23-C104)	23"-92"	138"-198"		
	23"-92"	138"-198"		
Inter-H-L (h 5-CL 126)	221"-218"	221"-218"		
Inter-H-H (h 11, h 14)	227"-227"	230-230"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

298, 298"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

mizagliflozinum

mizagliflozin



3-[[3-(4-[[3-(β-D-glucopyranosyloxy)-5-(propan-2-yl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy)propyl]amino]-2,2-dimethylpropanamide

mizagliflozine

3-[[3-(4-[[3-(β-D-glucopyranosyloxy)-5-(propan-2-yl)-1H-pyrazol-4-yl]methyl]-3-méthylphénoxy)propyl]amino]-2,2-diméthylpropanamide

mizagliflozina

3-[[3-(4-[[3-(β-D-glucopiranosiloxi)-5-(propan-2-il)-1H-pirazol-4-il]metil]-3-metilfenoxi)propil]amino]-2,2-dimetilpropanamida

**nafithromycinum**

nafithromycin



(3*R*,3'*1*Z,3*a*S,4*R*,6*R*,8*R*,9*R*,10*R*,12*R*,15*R*,15*a*S)-15-ethyl-8-methoxy-4,6,8,10,12,15*a*-hexamethyl-2,5,11,13-tetraoxo-*N'*-{(1*S*)-1-[5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl]ethoxy}-9-[[3,4,6-trideoxy-3-(dimethylamino)-β-*D*-xylo-hexopyranosyl]oxy]tetradecahydro-2*H*-furo[2,3-*c*]oxacyclotetradecine-3-carboximidamide

nafithromycine

(3*R*,3'*1*Z,3*a*S,4*R*,6*R*,8*R*,9*R*,10*R*,12*R*,15*R*,15*a*S)-15-éthyl-8-méthoxy-4,6,8,10,12,15*a*-hexaméthyl-2,5,11,13-tétraoxo-*N'*-{(1*S*)-1-[5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl]éthoxy}-9-[[3,4,6-tridéoxy-3-(diméthylamino)-β-*D*-xylo-hexopyranosyl]oxy]tétradécahydro-2*H*-furo[2,3-*c*]oxacyclotétradécine-3-carboximidamide

nafitromicina

(3*R*,3'*1*Z,3*a*S,4*R*,6*R*,8*R*,9*R*,10*R*,12*R*,15*R*,15*a*S)-15-etil-8-metoxi-4,6,8,10,12,15*a*-hexametil-2,5,11,13-tetraoxo-*N'*-{(1*S*)-1-[5-(piridin-2-il)-1,3,4-tiadiazol-2-il]etoxi}-9-[[3,4,6-tridesoxi-3-(dimetilamino)-β-*D*-xilo-hexopiranosil]oxi]tetradecahidro-2*H*-furo[2,3-*c*]oxaciclometradecina-3-carboximidamida

**naratuximabum #**

naratuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD37 (tetraspanin-26, TSPAN26)], chimeric monoclonal antibody;

gamma1 heavy chain (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), hinge (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444) (116-444)], (218-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 -IGKJ1*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (224-224'':227-227'')-bisdisulfide

naratuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* CD37 (tétraspamine-26, TSPAN26)], anticorps monoclonal chimérique;
chaîne lourde gamma1 (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), charnière (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444) (116-444)], (218-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 -IGKJ1*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (224-224'':227-227'')-bisdisulfure

naratuximab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* CD37 (tetraspanina-26, TSPAN26)], anticuerpo monoclonal quimérico;
cadena pesada gamma1 (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD) -IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), bisagra (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444) (116-444)], (218-214')-disulfuro con cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 -IGKJ1*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQVQESGPG LVAPSQTLSI TCTVSGFSLT TSGVSWVRQP PGKGLEWLGV 50
IWGDGSTNYH PSLKSRLSIK KDHSKQVFL KLSLTAAAT ATYYCAKGGY 100
SLAHWGQGTLT VTVSASTKG PSVFPLAPSS KTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVTVPSST LGTQTYICNV 200
NHKPSNTKVD KKEPKSCDK THTCPPCPAP ELLGSPSVFL FPPKPKDTLM 250
ISRTPETVTCV VVDVSHEDPE VKFNWYVDGV EVHNAKTKPR EEQYNSTYRV 300
VSVLTIVLHQP WINGKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLF 350
PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
SFFFLYSLTV DKSRWQGNV FSCSVMEAL HNHYTQKSLT LSPG 444
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSVSGGERVT ITCRASENIR SNLAWYQQKP GKSPKLLNVN 50
ATNLADGVPS RFGSGSGSTD YSLKINSIQP EDFGTYYCQH YWGTWTTFGQ 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-95	142-198	259-319	365-423
	22"-95"	142"-198"	259"-319"	365"-423"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L (h 5-CL 126)	218-214'	218"-214'"		
Inter-H-H (h 11, h 14)	224-224"	227-227'"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

295, 295"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

naratuximabum emtansinum #

naratuximab emtansine

immunoglobulin G1-kappa, anti-[*Homo sapiens*CD37 (tetraspanin-26, TSPAN26)], chimeric monoclonal antibody conjugated to maytansinoid DM1; gamma1 heavy chain (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), hinge (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (116-444)], (218-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 - IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (224-224'':227-227'')-bisdisulfide; conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM1 via a succinimidyl-4-(*N*-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker forming a nonreducible thioether bond

For the emtansine part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others".

naratuximab emtansine

immunoglobuline G1-kappa, anti-[*Homo sapiens*CD37 (tétraspamine-26, TSPAN26)], anticorps monoclonal chimérique conjugué au maytansinoïde DM1; chaîne lourde gamma1 (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), charnière (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (116-444)], (218-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 - IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (224-224'':227-227'')-bisdisulfure; conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM1 via un linker succinimidyl-4-(*N*-maléimidométhyl) cyclohexane-1-carboxylate (SMCC) formant une liaison thioéther non réductible

Pour la partie emtansine, veuillez-vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others".

naratuximab emtansina

immunoglobulina G1-kappa, anti-[*Homo sapiens*CD37 (tetraspanina-26, TSPAN26)], anticuerpo monoclonal quimérico conjugado con maitansinoide DM1; cadena pesada gamma1 (1-444) [*Mus musculus* VH (IGHV2-3*01 -(IGHD)- IGHJ3*01) [8.7.9] (1-115) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (116-213), bisagra (214-228), CH2 (229-338), CH3 (339-443), CHS K2>del (444)) (116-444)], (218-214')-disulfuro con cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV12-46*01 - IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (224-224'':227-227'')-bisdisulfuro; conjugado, en una media de 3 a 4 restos lisil, con maitansinoide DM1 mediante un conector succinimidil-4-(*N*-maleimidometil) ciclohexano-1-carboxilato (SMCC) formando una unión tioéter no reducible

La fracción emtansina se pueden encontrar en el documento "INN for pharmaceutical substances: Names for radicals, groups and others".

Heavy chain / Chaîne lourde / Cadena pesada

QVQVESGPG LVAPSQTLST TCTVSGFSLT TSGVSWVRQP PGKGLEWLGV 50
 IWGDGSTNYH PSLKSRLSIK KDHSKSQVFL KLSLTAADT ATYYCAKGGY 100
 SLAHWGQGT LVTSSASTKG PSVFPLAPSS KSTSGGTAAAL GCLVKDYFPE 150
 PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGTQTYICNV 200
 NHHKPSNTKVD KKEVPKSCDK THTCPCPAP ELLGGPSVFL FPPKPKDTLM 250
 ISRTPEVTCV VVDVSHEDPE VKFNWYVDG EVHNAKTKPR EEQYNSTYRV 300
 VSVLTVLHQD WLNKEYKCK VSNKALPAPI EKTISKAKGQ PREPQVYTLF 350
 PSRDELTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 400
 SFFLYSKLTIV DKSRRWQGNV FSCSVHREAL HNHYTQKSL LSPG 444

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSVSVGERVT ITCRASENIR SNLAWYQQKPK GKSPKLLVNV 50
 ATNLADGVPS RFGSGSGSTD YSLKINSLOP EDFGTYYCQH YWGTTWTFGQ 100
 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-95 142-198 259-319 365-423
 22"-95" 142"-198" 259"-319" 365"-423"

Intra-L (C23-C104) 23'-88' 134'-194'
 23'''-88''' 134'''-194'''

Inter-H-L (h 5-CL 126) 218-214' 218"-214"

Inter-H-H (h 11, h 14) 224-224" 227-227"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

295, 295"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes
 fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

An average of 3 to 4 lysyl being conjugated each to a drug linker / 3 à 4 lysyl en moyenne sont
 conjugués à un linker-principe actif / Una media de 3 a 4 lisil están conjugadas a conectores-principio
 activo.

navamepentum

navamepent

propan-2-yl (5*S*,8*E*,10*E*,12*R*)-5,12-dihydroxypentadeca-
 8,10-diene-6,14-diynoate


navamépént

(5*S*,8*E*,10*E*,12*R*)-5,12-dihydroxypentadéca-8,10-diène-
 6,14-diynoate de propan-2-yle

navamepent

(5*S*,8*E*,10*E*,12*R*)-5,12-dihidroxipentadeca-8,10-dieno-
 6,14-diinoato de propan-2-ilo

C₁₈H₂₄O₄



navicixizumabum

navicixizumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* DLL4
 (delta-like 4)] and anti-[*Homo sapiens* VEGFA (vascular
 endothelial growth factor A, VEGF-A, VEGF)], humanized
 and chimeric monoclonal antibody, bispecific;

	gamma2 heavy chain, humanized anti-DLL4 (1-445) [humanized VH (<i>Homo sapiens</i> IGHV1-18*01 (84.70%) - (IGHD)-IGHJ4*01) [8.8.12] (1-119) -<i>Homo sapiens</i> IGHG2*01 (CH1 (120-217), hinge (218-229), CH2 (230-338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)], (133-218')-disulfide with kappa light chain, chimeric (1'-218') [chimeric V-KAPPA (<i>Mus musculus</i> IGKV3-2*01 -<i>Homo sapiens</i> IGKJ1*01) [10.3.9] (1'-111') -<i>Homo sapiens</i> IGKC*01, Km3 (112'-218'')]; gamma2 heavy chain, humanized anti-VEGFA (1-447) [humanized VH (<i>Homo sapiens</i> IGHV1-46*01 (83.30%) - (IGHD)-IGHJ4*01) [8.8.14] (1-121) -<i>Homo sapiens</i> IGHG2*01 (CH1(122-219), hinge (220-231), CH2 (232-340), CH3 (341-445) E13>K(357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218''')-disulfide with kappa light chain, chimeric (1'''-218''') [chimeric V-KAPPA (<i>Mus musculus</i> IGKV3-2*01 -<i>Homo sapiens</i> IGKJ1*01) [10.3.9] (1'''-111''') -<i>Homo sapiens</i> IGKC*01, Km3 (112'''-218''')]; dimer (221-223":222-224":225-227":228-230")-tetrakisdisulfide
navicixizumab	immunoglobuline G2-kappa, anti-[<i>Homo sapiens</i> DLL4 (delta-like 4)] et anti-[<i>Homo sapiens</i> VEGFA (facteur de croissance A de l'endothélium vasculaire, VEGF-A, VEGF)], anticorps monoclonal humanisé et chimérique, bispécifique; chaîne lourde gamma2, humanisée anti-DLL4 (1-445) [VH humanisé (<i>Homo sapiens</i> IGHV1-18*01 (84.70%) - (IGHD)-IGHJ4*01) [8.8.12] (1-119) -<i>Homo sapiens</i> IGHG2*01 (CH1 (120-217), charnière (218-229), CH2 (230-338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)], (133-218')-disulfure avec la chaîne légère kappa, chimérique (1'-218') [V-KAPPA chimérique (<i>Mus musculus</i> IGKV3-2*01 -<i>Homo sapiens</i> IGKJ1*01) [10.3.9] (1'-111') -<i>Homo sapiens</i> IGKC*01, Km3 (112'-218'')]; chaîne lourde gamma2, humanisée anti-VEGFA (1-447) [VH humanisé (<i>Homo sapiens</i> IGHV1-46*01 (83.30%) - (IGHD)-IGHJ4*01) [8.8.14] (1-121) -<i>Homo sapiens</i> IGHG2*01 (CH1 (122-219), charnière (220-231), CH2 (232-340), CH3 (341-445) E13>K (357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218''')-disulfure avec la chaîne légère kappa, chimérique (1'''-218''') [V-KAPPA chimérique (<i>Mus musculus</i> IGKV3-2*01 -<i>Homo sapiens</i> IGKJ1*01) [10.3.9] (1'''-111''') -<i>Homo sapiens</i> IGKC*01, Km3 (112'''-218''')]; dimère (221-223":222-224":225-227":228-230")-tétrakisdisulfure
navicixizumab	immunoglobulina G2-kappa, anti-[<i>Homo sapiens</i> DLL4 (delta-like 4)] y anti-[<i>Homo sapiens</i> VEGFA (factor de crecimiento A del endotelio vascular, VEGF-A, VEGF)], anticuerpo humanizado y quimérico, biespecífico;

cadena pesada gamma2, humanizada anti-DLL4 (1-445) [VH humanizado (*Homo sapiens* IGHV1-18*01 (84.70%) - (IGHD)-IGHJ4*01) [8.8.12] (1-119) -*Homo sapiens* IGHG2*01 (CH1 (120-217), bisagra (218-229), CH2 (230-338), CH3 (339-443) K26>E (368), K88>E (407), CHS (444-445)) (120-445)], (133'-218')-disulfuro con la cadena ligera kappa, quimérica (1'-218') [V-KAPPA quimérico (*Mus musculus* IGKV3-2*01 -*Homo sapiens* IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; cadena pesada gamma2, humanizada anti-VEGFA (1-447) [VH humanizado (*Homo sapiens* IGHV1-46*01 (83.30%) - (IGHD)-IGHJ4*01) [8.8.14] (1-121) -*Homo sapiens* IGHG2*01 (CH1(122-219), bisagra (220-231), CH2 (232-340), CH3 (341-445) E13>K(357), D84.2>K (399), CHS (446-447)) (122-447)], (135'-218'')-disulfuro con la cadena ligera kappa, quimérica (1'''-218''') [V-KAPPA quimérico (*Mus musculus* IGKV3-2*01 -*Homo sapiens* IGKJ1*01) [10.3.9] (1'''-111''') -*Homo sapiens* IGKC*01, Km3 (112'''-218''')]; dímero (221-223'':222-224'':225-227'':228-230'')-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada (anti-DLL4, 1-445)
 QVQLVQSGAE SCKPGASVKV SKKPSGYTFT NYMMHWVRQ PGQGLEWIGY 50
 ISNYNRATNY NQKFKGRVTF TDDTSTSTAY MELSLRSDD TAVYYCARDY 100
 DYDVGMDYWG OGTLVTVSSA STKGPSVFL APCSRSTSES TAALGCLVKD 150
 YFPDPFVTSW NSGALISGVH TEPAYVLOSSG LYSLSSTVTV FSNFSGTQTV 200
 TCVVDHKPSN TKVDKTFBKK CQVECPFCFA PFVAGPSVEL FPKPKRDTLM 250
 ISRTPEVTVCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEOFNSTFRV 300
 VSVLTIVVHD WLNKREYKCK VSNKGLPAPI EKTISKTKGQ PREPOVYITLP 350
 PSREEMTKQ VSLTCLVPEF YPSDIAVBEW SNGQEPNNYK TTPPMLDSDO 400
 SFFLYSELTV DKSRWQGNV FSCSVMEAL HNHYTKSLS LSPGK 445

Heavy chain / Chaîne lourde / Cadena pesada (anti-VEGFA, 1'-447')
 QVQLVQSGAE VKKPGASVKV SCKPSGYTFT NYMMHWVRQ PGQGLEWMDG 50
 INPSNCRSTY KEKFKRRVTL SVDKSSSTAY MELSLRSDD TAVYFCTIHY 100
 DDKYYPIMDY WGQGLTVTS SASTKGPSVF FLAPCSRSTSES ESTAALGCLV 150
 KDYFPEFVTV SWNSGALISGV VHTFPAYVLOSSG LYSLSSTVTV FSNFSGTQTV 200
 TYTCNVVDHKP SNTKVDKTFE RKCCVECPFCFA PAPPVAGPSV FLEPKPKRDT 250
 LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEOFNSTF 300
 RVVSVLTIVVH ODWLNKREYK CKVSNKGLPA PIEKTI SKTK GOPREPOVYIT 350
 LPPREEMTKQ NOVSLTCLVPEF YPSDIAVBEW SNGQEPNNYK TTPPMLDSDO 400
 DGSFFLYSKL TVDKSRWQGNV FSCSVMEAL ALHNHYTKSLS LSLSPGK 447

Light chain / Chaîne légère / Cadena ligera
 DIVMTQSPDS LAVSLGERAT ISCRASESD NYGISFMKWF OOKPGQPPKL 50
 LIYAASNOGS GVPDRFSGSG SGTDFTLTIS SLOAEDVAVY YCOOSREVPW 100
 TFGGGRKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCCLL NNFYPREAKV 150
 QKRYDALDSK GNSQSVTQQ DSKDSTYSLT STLTLSKADY EKRHYVYACEV 200
 THQGLSSPVT KSFNRGEC 218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 146-202 259-319 365-423
 22'-96" 148"-204" 261"-321" 367"-425"
 Intra-L (C23-C104) 23'-97 138'-198"
 23"-92" 138"-198"
 Inter-H-L (CH1 10-CL 126) 133-218' 135'-218"
 Inter-H-H (h 4, h 5, h 11, h 14) 221-223" 222-224" 225-227" 228-230"

*In addition to the isoform A, isoform B characterized by two inter-H-H (h 5-CH1 10) (222-135', 224'-133) and two inter-H-L (h 4-CL 126) (221-218', 223'-218'), instead of the inter-H-H (h 4-h 4, h 5-h 5) and the two inter-H-L (CH1 10-CL 126), and two isoforms A/B characterized by one inter-H-H (h 4-CH1 10) and one inter-H-L (h 4-CL 126) (221-135' and 223'-218', respectively, in one isoform A/B, 223'-133 and 221-218', respectively, in the other one), instead of the inter-H-H (h 4-h 4) and one inter-H-L (CH1 10-CL 126). It is not excluded that other disulfide bridges may occur between the same cysteines.

*En plus de l'isoforme A, l'isoforme B caractérisée par un inter-H-H (h 5-CH1 10) (222-135', 224'-133) et deux inter-H-L (h 4-CL 126) (221-218', 223'-218'), au lieu des inter-H-H (h 4-h 4, h 5-h 5) et des deux inter-H-L (CH1 10-CL 126), et deux isoformes A/B caractérisées par un inter-H-H (h 4-CH1 10) et un inter-H-L (h 4-CL 126) (221-135' et 223'-218', respectivement, dans une isoforme A/B, 223'-133 et 221-218', respectivement, dans l'autre), au lieu de l'inter-H-H (h 4-h 4) et d'un inter-H-L (CH1 10-CL 126). Il n'est pas exclu que d'autres ponts disulfures existent entre les mêmes cystéines.

*Además de la isoforma A, isoforma B caracterizada por un inter-H-H (h 5-CH1 10) (222-135', 224'-133) y dos inter-H-L (h 4-CL 126) (221-218', 223'-218'), en lugar de los inter-H-H (h 4-h 4, h 5-h 5) y de los dos inter-H-L (CH1 10-CL 126), y dos isoformas A/B caracterizadas por un inter-H-H (h 4-CH1 10) y un inter-H-L (h 4-CL 126) (221-135' y 223'-218', respectivamente, dentro una isoforma A/B, 223'-133 y 221-218', respectivamente, dentro el otra), en lugar de l'inter-H-H (h 4-h 4) y de uno inter-H-L (CH1 10-CL 126). No se excluye que otros puentes disulfuro existan entre las mismas cisteínas.

nazartinibum
 nazartinib


N-(7-chloro-1-[(3*R*)-1-[(2*E*)-4-(dimethylamino)but-2-enoyl]azepan-3-yl]-1*H*-benzimidazol-2-yl)-2-methylpyridine-4-carboxamide

nazartinib

N-(7-chloro-1-[(3*R*)-1-[(2*E*)-4-(diméthylamino)but-2-énoyl]azépan-3-yl]-1*H*-benzimidazol-2-yl)-2-méthylpyridine-4-carboxamide

nazartinib

N-(7-chloro-1-((3*R*)-1-[(2*E*)-4-(dimetilamino)but-2-enil]azepan-3-il)-1*H*-benzimidazol-2-il)-2-metilpiridina-4-carboxamida

 $C_{26}H_{31}ClN_6O_2$


nicodicosapentum

nicodicosapent


N-{2-[(5*Z*,8*Z*,11*Z*,14*Z*,17*Z*)-icosa-5,8,11,14,17-pentaenamido]ethyl}pyridine-3-carboxamide

nicodicosapent

N-{2-[(5*Z*,8*Z*,11*Z*,14*Z*,17*Z*)-icosa-5,8,11,14,17-pentaénamido]éthyl}pyridine-3-carboxamide

nicodicosapent

N-{2-[(5*Z*,8*Z*,11*Z*,14*Z*,17*Z*)-icosa-5,8,11,14,17-pentaenamido]etil}piridina-3-carboxamida

 $C_{28}H_{39}N_3O_2$


nolasibanum

nolasiban


[(2*S*,4*Z*)-2-(hydroxymethyl)-4-(methoxyimino)pyrrolidin-1-yl](2'-methyl[1,1'-biphenyl]-4-yl)methanone

nolasiban

[(2*S*,4*Z*)-2-(hydroxyméthyl)-4-(méthoxyimino)pyrrolidin-1-yl](2'-méthyl[1,1'-biphényl]-4-yl)méthanone

nolasibán

(2*S*,4*Z*)-2-(hidroximetil)-4-(metoxiimino)pirrolidin-1-il](2'-metil[1,1'-bifenil]-4-il)metanona

 $C_{20}H_{22}N_2O_3$


oliceridinum


oliceridine

N-[(3-methoxythiophen-2-yl)methyl]-2-[(9*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]decan-9-yl]ethan-1-amine

olicéridine *N*-[(3-méthoxythiophén-2-yl)méthyl]-2-[(9*R*)-9-(pyridin-2-yl)-6-oxaspiro[4.5]décan-9-yl]éthan-1-amine

oliceridina *N*-[(3-metoxitiofen-2-il)metil]-2-[(9*R*)-9-(piridin-2-il)-6-oxaspiro[4.5]decan-9-il]etan-1-amina

$C_{22}H_{30}N_2O_2S$




olmutinibum
olmutinib

N-[3-({2-[4-(4-méthylpiperazin-1-yl)anilino]thieno[3,2-*d*]pyrimidin-4-yl}oxy)phényl]prop-2-énamide

olmutinib *N*-[3-({2-[4-(4-méthylpipérazin-1-yl)anilino]thiéno[3,2-*d*]pyrimidin-4-yl}oxy)phényl]prop-2-énamide

olmutinib *N*-[3-({2-[4-(4-metilpiperazina-1-il)anilino]tieno[3,2-*d*]pirimidin-4-il}oxi)fenil]prop-2-énamida

$C_{26}H_{26}N_6O_2S$




olumacostatum glasaretilum
olumacostat glasaretil

2-[(2-éthoxy-2-oxoéthyl)(méthyl)amino]-2-oxoéthyl 5-(tétradécyloxy)furan-2-carboxylate

olumacostat glasarétil 5-(tétradécyloxy)furane-2-carboxylate de 2-[(2-éthoxy-2-oxoéthyl)(méthyl)amino]-2-oxoéthyle

olumacostat glasaretilo 5-(tetradeciloxi)furan-2-carboxilato de 2-[(2-etoxi-2-oxoetil)(metil)amino]-2-oxoetilo

$C_{26}H_{43}NO_7$



omidenepagum

omidenepag


{{6-[(*N*-{[4-(1*H*-pyrazol-1-yl)phenyl]methyl}pyridine-3-sulfonamido)methyl]pyridin-2-yl}amino)acetic acid

omidénépag

acide {{6-[(*N*-{[4-(1*H*-pyrazol-1-yl)phényl]méthyl}pyridine-3-sulfonamido)méthyl]pyridin-2-yl}amino)acétique

omidenepag

ácido {{6-[(*N*-{[4-(1*H*-pirazol-1-il)fenil]metil}piridina-3-sulfonamido)metil]piridin-2-il}amino)acético

C₂₃H₂₂N₆O₄S**oteseconazolum**

oteseconazole


(2*R*)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1*H*-1,2,3,4-tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]pyridin-2-yl]propan-2-ol

otéséconazole

(2*R*)-2-(2,4-difluorophényl)-1,1-difluoro-3-(1*H*-1,2,3,4-tétrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroéthoxy)phényl]pyridin-2-yl]propan-2-ol

oteseconazol

(2*R*)-2-(2,4-difluorofenil)-1,1-difluoro-3-(1*H*-1,2,3,4-tetrazol-1-il)-1-[5-[4-(2,2,2-trifluoroetoxi)fenil]piridin-2-il]propan-2-ol

C₂₃H₁₆F₇N₅O₂**pibrentasvirum**

pibrentasvir


dimethyl *N,N'*-([[(2*R*,5*R*)-1-{3,5-difluoro-4-[4-(4-fluorophenyl)piperidin-1-yl]phenyl}pyrrolidine-2,5-diyl]bis[(6-fluoro-1*H*-benzimidazole-5,2-diyl)][(2*S*)-pyrrolidine-2,1-diyl][(2*S*,3*R*)-3-methoxy-1-oxobutane-1,2-diyl]])dicarbamate

pibrentasvir

N,N'-([[(2*R*,5*R*)-1-{3,5-difluoro-4-[4-(4-fluorophényl)pipéridin-1-yl]phényl}pyrrolidine-2,5-diyl]bis{(6-fluoro-1*H*-benzimidazole-5,2-diyl)[(2*S*)-pyrrolidine-2,1-diyl][(2*S*,3*R*)-3-méthoxy-1-oxobutane-1,2-diyl]})dicarbamate de diméthyle

pibrentasvir

N,N'-([[(2*R*,5*R*)-1-{3,5-difluoro-4-[4-(4-fluorofenil)piperidin-1-il]fenil}pirrolidina-2,5-diil]bis{(6-fluoro-1*H*-benzimidazol-5,2-diil)[(2*S*)-pirrolidina-2,1-diil][(2*S*,3*R*)-3-metoxi-1-oxobutano-1,2-diil]})dicarbamato de dimetil

C₅₇H₆₅F₆N₁₀O₈**prexasertibum**

prexasertib


5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1*H*-pyrazol-3-yl}amino)pyrazine-2-carbonitrile

prexasertib

5-({5-[2-(3-aminopropoxy)-6-méthoxyphényl]-1*H*-pyrazol-3-yl}amino)pyrazine-2-carbonitrile

prexasertib

5-({5-[2-(3-aminopropoxi)-6-metoxifenil]-1*H*-pirazol-3-il}amino)pirazina-2-carbonitrilo

C₁₈H₁₉N₇O₂

prexigebersenum

prexigebersen

2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-
 2'-deoxyadenylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-
 (3'→5')-thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-
 2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-
 2'-deoxyguanylyl-(3'→5')-2'-deoxyadenylyl-(3'→5')-
 thymidylyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-
 2'-deoxyguanylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-
 thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-deoxycytidine

prexigébersen

2'-déoxyadénylyl-(3'→5')-thymidylyl-(3'→5')-
 2'-déoxyadénylyl-(3'→5')-thymidylyl-(3'→5')-thymidylyl-
 (3'→5')-thymidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-
 2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-
 2'-déoxyguanylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-
 thymidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-
 2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-
 thymidylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxycytidine

prexigebersén

2'-desoxiadenilil-(3'→5')-timidilil-(3'→5')-2'-desoxiadenilil-
 (3'→5')-timidilil-(3'→5')-timidilil-(3'→5')-timidilil-(3'→5')-
 2'-desoxiguanilil-(3'→5')-2'-desoxiguanilil-(3'→5')-
 2'-desoxicitidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-
 2'-desoxiadenilil-(3'→5')-timidilil-(3'→5')-2'-desoxiguanilil-
 (3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicitidilil-(3'→5')-
 timidilil-(3'→5')-timidilil-(3'→5')-2'-desoxicitidina

C₁₇₇H₂₂₄N₆₃O₁₁₀P₁₇

(3'-5')d(A-T-A-T-T-G-G-C-G-A-T-G-G-C-T-T-C)

prezalumabum #

prezalumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* ICOSL
 (inducible T-cell co-stimulatory ligand, B7 homologue 2,
 B7H2, B7-H2, B7-related protein 1, B7RP1, B7RP-1,
 CD275)], *Homo sapiens* monoclonal antibody;
 gamma2 heavy chain (1-447) [*Homo sapiens* VH (IGHV3-
 7*01 (98.00%) -(IGHD) -IGHJ2*01) [8.8.14] (1-121) -
 IGHG2*01, G2m.. (CH1 (122-219), hinge (220-231), CH2
 (232-340), CH3 (341-445), CHS (446-447)) (122-447)],
 (135-214')-disulfide with kappa light chain (1'-214') [*Homo*
sapiens V-KAPPA (IGKV2D-16*01 (97.90%) -IGKJ1*01)
 [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (223-
 223":224-224":227-227":230-230")-tetrakisdisulfide

préalumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* ICOSL
 (ligand inductible co-stimulateur des cellules T, homologue
 2 du B7, B7H2, B7-H2, protéine 1 apparentée au B7,
 B7RP1, B7RP-1, CD275)], *Homo sapiens* anticorps
 monoclonal;
 chaîne lourde gamma2 (1-447) [*Homo sapiens* VH
 (IGHV3-7*01 (98.00%) -(IGHD) -IGHJ2*01) [8.8.14] (1-
 121) -IGHG2*01, G2m.. (CH1 (122-219), charnière (220-
 231), CH2 (232-340), CH3 (341-445), CHS (446-447))
 (122-447)], (135-214')-disulfure avec la chaîne légère
 kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV2D-16*01
 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-
 214')]; dimère (223-223":224-224":227-227":230-230")-
 tétrakisdisulfure

prezalumab

inmunoglobulina G2-kappa, anti-[*Homo sapiens* ICOSL (ligando inducible co-estimulador de las células T, B7 homólogo 2, B7H2, B7-H2, proteína 1 relacionada con la B7, B7RP1, B7RP-1, CD275)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma2 (1-447) [*Homo sapiens* VH (IGHV3-7*01 (98.00%) -(IGHD) -IGHJ2*01) [8.8.14] (1-121) -IGHG2*01, G2m.. (CH1 (122-219), bisagra (220-231), CH2 (232-340), CH3 (341-445), CHS (446-447)) (122-447)], (135-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV2D-16*01 (97.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dímero (223-223":224-224":227-227":230-230")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGTFES SYWMSWVRQA PGKLEWVAY 50
IKQDNEKYY VDSVKGRFTI SRDANKSLY LQMSLRAED TAVYYCAREG 100
ILWFGDLPTF WQQGTILVTVS SASTKGPSVF PLAPCSRSTS ESTAALGCLV 150
KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSNFGTQ 200
TYTCNVDHKP SNTKVDKTVK RKCCVECPFC PAPPVAGPSV FLFPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF 300
RVVSVLTIVH QDWLNGKEYK CKVSNKGLPA PIEKTSKTK GQPREPQVYT 350
LPPSREEMTK NOVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPMLDS 400
DGSFFLYSKL TVDKSRWQGG NVFSCSVHME ALHNYHTQKS LSLSPGK 447
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGDRTV ITCRASQGIS NWLAWYQQK EKAPKSLIYA 50
ASSLQSGVPS RFGSGSGTD FTLTISSLOP EDFATYYCQ YDSYPRTFGQ 100
GTKVEIKRTV AAPSVFIPTP SDEQLKSGTA SVVCLLNFPY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYSLSTLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGEC 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	148-204	261-321	367-425
	22"-96"	148"-204"	261"-321"	367"-425"
Intra-L (C23-C104)	23'-88'	134'-194'		
	23'''-88'''	134'''-194'''		
Inter-H-L (CH1 10-CL 126)	135-214'	135"-214"		
Inter-H-H (h 4, h 5, h 8, h 11)	223-223"	224-224"	227-227"	230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

297, 297"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

redaporfinum

redaporfin



3,3',3",3'''-(7,8,17,18-tetrahydroporphyrin-5,10,15,20-tetrayl)tetrakis(2,4-difluoro-*N*-methylbenzenesulfonamide)

redaporfine

3,3',3",3'''-(7,8,17,18-tétrahydroporphyrin-5,10,15,20-tétrayl)tétrakis(2,4-difluoro-*N*-méthylbenzènesulfonamide)

redaporfina

3,3',3",3'''-(7,8,17,18-tetrahidroporfirin-5,10,15,20-tetrail)tetrakis(2,4-difluoro-*N*-metilbencenosulfonamida)



refanezumabum #
refanezumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MAG (myelin associated glycoprotein, sialic acid binding Ig-like lectin 4A, SIGLEC4A, SIGLEC-4A)], humanized monoclonal antibody;
gamma1 heavy chain (1-456) [humanized VH (*Homo sapiens* IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (127-224), hinge (225-239), CH2 L1.2>A (244), G1>A (246) (240-349), CH3 (350-454), CHS (455-456)) (127-456)], (229-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219')]; dimer (235-235":238-238")-bisdisulfide

réfanézumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MAG (glycoprotéine associée à la myéline, lectine 4A Ig-like liant l'acide sialique, SIGLEC4A, SIGLEC-4A)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-456) [humanisé VH (*Homo sapiens* IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (127-224), charnière (225-239), CH2 L1.2>A (244), G1>A (246) (240-349), CH3 (350-454), CHS (455-456)) (127-456)], (229-219')- disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219')]; dimère (235-235":238-238")-bisdisulfure

refanezumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MAG (glicoproteína asociada a la mielina, lectina de tipo inmunoglobulina 4A que se une al ácido siálico, SIGLEC4A, SIGLEC-4A)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-456) [VH humanizado (*Homo sapiens* IGHV7-4-1*02 (93.90%) -(IGHD)-IGHJ4*01) [8.8.19] (1-126) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (127-224), bisagra (225-239), CH2 L1.2>A (244), G1>A (246) (240-349), CH3 (350-454), CHS (455-456)) (127-456)], (229-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (95.00%) -IGKJ2*01) [12.3.8] (1'-112') -*Homo sapiens* IGKC*01, Km3 (113'-219')]; dímero (235-235":238-238")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGSE LKPGASVKV SCKASGYTFT NYGMNVRQA PGQGLEWMGW 50
INTYTGPTY ADDFTGRFVF SLDTSVSTAY LQISSLKAED TAVYVCARNP 100
INYYGINYEG YVMDYWGQGT LVTSSASTK GPSVFFPLAPS SKSTSGGTAA 150
LGCLVKDYFN EPVTYVWNSG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS 200
SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPCPA PELAGAPSVF 250
LFPKPKDITL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP 300
REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNNKALPAP IEKTIISKAG 350
QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY 400
KTPFPVLDSD GSFFLYSKLT VDKSRWQGN VFSCSVMHEA LHNHYTQKSL 450
SLSPGK 456

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPDS LAVSLGERAT INCKSSHSVL YSSNQKNYLA WYQKPGQPP 50
KLLIYWASTR ESGVPRDFSG SGSSTDFTLT ISSLQAEDVA VYCHQYLSS 100
LTFGQGTKLE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYPREAK 150
VQWVKVDNALQ SGNSQESVTE QDSKDSYSL SSTLTLSKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNREGC 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 153-209 270-330 376-434
22"-96" 153"-209" 270"-330" 376"-434"
Intra-L (C23-C104) 23"-94" 139"-199"
23"-94" 139"-199"
Inter-H-L (h 5-CL 126) 229-219" 229"-219"
Inter-H-H (h 11, h 14) 235-235" 238-238"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

306, 306"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

revefenacinum

revefenacin



1-(2-{4-[(4-carbamoylpiperidin-1-yl)methyl]-*N*-methylbenzamido}ethyl)piperidin-4-yl *N*-([1,1'-biphenyl]-2-yl)carbamate

révéfénacine

N-([1,1'-biphenyl]-2-yl)carbamate de 1-(2-{4-[(4-carbamoylpipéridin-1-yl)méthyl]-*N*-méthylbenzamido}éthyl)pipéridin-4-yle

revefenacina

N-([1,1'-bifenil]-2-il)carbamato de 1-(2-{4-[(4-carbamoiipiperidin-1-il)metil]-*N*-metilbenzamida}etil)piperidin-4-il



rivabazumabum #
rivabazumab

immunoglobulin Fab' G1-kappa, anti-[*Pseudomonas aeruginosa* type III secretion system (TTSS) PcrV protein], humanized monoclonal antibody;
gamma1 heavy chain fragment VH-(CH1-hinge) (1-238) [humanized VH (*Homo sapiens* IGHV3-30*06 (92.90%) - (IGHD) -IGHJ6*01) [8.8.17] (1-124) -*Homo sapiens* IGHG1*01 (CH1 (125-222), hinge C5>S (227) (223-237), CH2 (238)) (125-238)], noncovalently associated with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC*01 C126>S (214') (108'-214')]

rivabazumab

immunoglobuline Fab' G1-kappa, anti-[protéine PcrV du système de sécrétion type III (TTSS) de *Pseudomonas aeruginosa*], anticorps monoclonal humanisé;
fragment VH-(CH1-charnière) de la chaîne lourde gamma1 (1-238) [VH humanisé (*Homo sapiens* IGHV3-30*06 (92.90%) - (IGHD) -IGHJ6*01) [8.8.17] (1-124) -*Homo sapiens* IGHG1*01 (CH1 (125-222), charnière C5>S (227) (223-237), CH2 (238)) (125-238)], associé de manière non covalente avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-5*01 (84.60%) - IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 C126>S (214') (108'-214')]

rivabazumab

immunoglobulina Fab' G1-kappa, anti-[proteína PcrV del sistema de secreción tipo III (TTSS) de *Pseudomonas aeruginosa*], anticuerpo monoclonal humanizado;
fragmento VH-(CH1-bisagra) de la cadena pesada gamma1 (1-238) [VH humanizado (*Homo sapiens* IGHV3-30*06 (92.90%) - (IGHD) -IGHJ6*01) [8.8.17] (1-124) - *Homo sapiens* IGHG1*01 (CH1 (125-222), bisagra C5>S (227) (223-237), CH2 (238)) (125-238)], asociado de modo no covalente con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-5*01 (84.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 C126>S (214') (108'-214')]

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG VVQPGKSLRL SCAASGFTFS NYPMHWRQA PGKGLEWVAV 50
ISYDGERKMY ADSVKGRTTI SRDNSKNTLY LEMNSLRPED TAVYYCARNR 100
GDIYYDFTYA MDIWGGQTTV TVSSASTKGP SVFPLAPSSK STSGGTAALG 150
CLVKDYFPEP VTSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTFPSSSL 200
GTQTYICNVN HKPSNTKVDK KVEPKSSDKT HTCPCCPA 238
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPST LSASVGDSTV ITCRASEGVD RLAWYQQKQ GRAPKLLIYD 50
ASTLQSGVPS RFGSGSGSTE FSLTISLQP DDVATYYCQH FWGTPYTFGQ 100
GTKLEIKRTV AAPSVFIFFP SDEQLKSGTA SVVCLLNFFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEHKK VYACEVTHQG 200
LSPSVTKSFN RGES 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 151-207

Intra-L (C23-C104) 23'-88' 134'-194'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

None

ruclosporinum

ruclosporin



8-[(2*R*)-*N*-methyl-2-[2-(4-morpholinyl)ethoxy]glycine]cyclosporin A:
 cyclo[L-alanyl-D-alanyl-*N*-methyl-L-leucyl-*N*-methyl-L-leucyl-*N*-methyl-L-valyl-(3*R*,4*R*,6*E*)-3-hydroxy-*N*,4-dimethyl-L-2-aminooct-6-enoyl-L-2-aminobutanoyl-(2*R*)-*N*-methyl-2-[2-(morpholin-4-yl)ethoxy]glycyl-*N*-methyl-L-leucyl-L-valyl-*N*-methyl-L-leucyl]

ruclosporine

8-[(2*R*)-*N*-méthyl-2-[2-(4-morpholinyl)éthoxy]glycine]cyclosporine A:
 cyclo[L-alanyl-D-alanyl-*N*-méthyl-L-leucyl-*N*-méthyl-L-leucyl-*N*-méthyl-L-valyl-(3*R*,4*R*,6*E*)-3-hydroxy-*N*,4-diméthyl-L-2-aminooct-6-énoyl-L-2-aminobutanoyl-(2*R*)-*N*-méthyl-2-[2-(morpholin-4-yl)éthoxy]glycyl-*N*-méthyl-L-leucyl-L-valyl-*N*-méthyl-L-leucyl]

ruclosporina

8-[(2*R*)-*N*-metil-2-[2-(4-morfolinil)etoxi]glicina]ciclosporina A:
 ciclo[L-alanil-D-alanil-*N*-metil-L-leucil-*N*-metil-L-leucil-*N*-metil-L-valil-(3*R*,4*R*,6*E*)-3-hidroxi-*N*,4-dimetil-L-2-aminooct-6-enoil-L-2-aminobutanoil-(2*R*)-*N*-metil-2-[2-(morfolin-4-il)etoxi]glicil-*N*-metil-L-leucil-L-valil-*N*-metil-L-leucil]



ruzasvirum

ruzasvir


dimethyl *N,N'*-([[(6*S*)-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-6*H*-indolo[1,2-*c*][1,3]benzoxazine-3,10-diyl]bis{[(1*H*-imidazole-4,2-diyl)[(2*S*)-pyrrolidine-2,1-diyl][(2*S*)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate

ruzasvir

N,N'-([[(6*S*)-6-(2-cyclopropyl-1,3-thiazol-5-yl)-1-fluoro-6*H*-indolo[1,2-*c*][1,3]benzoxazine-3,10-diyl]bis{[(1*H*-imidazole-4,2-diyl)[(2*S*)-pyrrolidine-2,1-diyl][(2*S*)-3-méthyl-1-oxobutane-1,2-diyl]})dicarbamate de diméthyle

ruzasvir

N,N'-([[(6*S*)-6-(2-ciclopropil-1,3-tiazol-5-il)-1-fluoro-6*H*-indolo[1,2-*c*][1,3]benzoxazina-3,10-diil]bis{[(1*H*-imidazol-4,2-diil)[(2*S*)-pirrolidina-2,1-diil][(2*S*)-3-metil-1-oxobutano-1,2-diil]})dicarbamato de dimetilo

C₄₉H₅₅FN₁₀O₇S**satoreotidum trizoxetanum**

satoreotide trizoxetan


*S*², *S*⁷-cyclo[*N*-{[(4*RS*)-4-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]-4-carboxybutanoyl]-4-chloro-L-phenylalanyl-D-cysteinyl-4-[(4*S*)-2,6-dioxo-1,3-diazinane-4-carb-oxamido]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteinyl-D-tyrosinamide]

satoréotide trizoxétan

*S*², *S*⁷-cyclo[*N*-{[(4*RS*)-4-[4,7-bis(carboxyméthyl)-1,4,7-triazonan-1-yl]-4-carboxybutanoyl]-4-chloro-L-phénylalanyl-D-cystéinyl-4-[(4*S*)-2,6-dioxo-1,3-diazinane-4-carb-oxamido]-L-phénylalanyl-4-(carbamoylamino)-D-phénylalanyl-L-lysyl-L-thréonyl-L-cystéinyl-D-tyrosinamide]

satoreotida trizoxetán

*S*², *S*⁷-ciclo[*N*-{[(4*RS*)-4-[4,7-bis(carboximetil)-1,4,7-triazonan-1-il]-4-carboxibutanoil]-4-cloro-L-fenilalanil-D-cisteinil-4-[(4*S*)-2,6-dioxo-1,3-diazinano-4-carboxamido]-L-fenilalanil-4-(carbamoilamino)-D-fenilalanil-L-lisil-L-treonil-L-cisteinil-D-tirosinamida]

**seviteronelum**



seviteronel

(1*S*)-1-[6,7-bis(difluoromethoxy)naphthalen-2-yl]-2-methyl-1-(1*H*-1,2,3-triazole-4-yl)propan-1-ol

sevitéronel

(1*S*)-1-[6,7-bis(difluorométhoxy)naphtalén-2-yl]-2-méthyl-1-(1*H*-1,2,3-triazole-4-yl)propan-1-ol

seviteronel

(1*S*)-1-[6,7-bis(difluorometoxi)naftalen-2-il]-2-metil-1-(1*H*-1,2,3-triazol-4-il)propan-1-ol**sitravatinibum**



sitravatinib

N-(3-fluoro-4-{{2-(5-{{[(2-methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-*b*]pyridin-7-yl}oxy}phenyl)-*N'*-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

sitravatinib

N-(3-fluoro-4-{{2-(5-{{[(2-méthoxyéthyl)amino]méthyl}pyridin-2-yl)thiéno[3,2-*b*]pyridin-7-yl}oxy}phényl)-*N'*-(4-fluorophényl)cyclopropane-1,1-dicarboxamide

sitravatinib

N-(3-fluoro-4-{{2-(5-{{[(2-metoxietil)amino]metil}piridin-2-il)tieno[3,2-*b*]piridin-7-il}oxi}fenil)-*N'*-(4-fluorofenil)ciclopropano-1,1-dicarboxamida

talinoxomerum

talinoxomer


poly[(prop-2-enoic acid)-co-{2-ethyl-2-[(prop-2-enoyloxy)methyl]propane-1,3-diyl di(prop-2-enoate)}]

talinoxomère

poly[(acide prop-2-énoïque)-co-{di(prop-2-énoate) de 2-éthyl-2-[(prop-2-énoyloxy)méthyl]propane-1,3-diyle}]

talinoxómero

poli[(ácido prop-2-enoico)-co-{di(prop-2-enoato de 2-etil-2-[(prop-2-enoiloxi)metil]propano-1,3-diilo)}]

[[C₁₅H₂₀O₆]_x · [C₃H₄O₂]_y]_n y/x ≈ 1000**tamtuvetmabum #**

tamtuvetmab

immunoglobulin G2_V-kappa-C-lambda, anti-[*Homo sapiens* CD52], caninized monoclonal antibody; gamma2 heavy chain chimeric (1-456) [chimeric VH (*Rattus norvegicus* IGHV7S6*01 (97.00%) -(IGHD) -*Canis lupus familiaris* IGHJ-E2RCC8) [8.10.12] (1-121) -*Canis lupus familiaris* IGHG2*02 (CH1 (122-219), hinge (220-237), CH2 (238-347), CH3 (348-454), CHS (455-456))(122-456)], (136-212')-disulfide with V-kappa-C-lambda light chain chimeric (1'-213') [*Rattus norvegicus* V-KAPPA (*Rattus norvegicus* IGKV22S7 (93.70%) -IGKJ1*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGLC1S1*01 V45.3>I (156) (108'-213')]; dimer (233-233":236-236")-bisdisulfide

tamtuvetmab

immunoglobuline G2_V-kappa-C-lambda, anti-[*Homo sapiens* CD52], anticorps monoclonal caninisé; chaîne lourde gamma2 chimérique (1-456) [VH chimérique (*Rattus norvegicus* IGHV7S6*01 (97.00%) -(IGHD) -*Canis lupus familiaris* IGHJ-E2RCC8) [8.10.12] (1-121) -*Canis lupus familiaris* IGHG2*02 (CH1 (122-219), charnière (220-237), CH2 (238-347), CH3 (348-454), CHS (455-456)) (122-456)], (136-212')-disulfure avec la chaîne légère V-kappa-C-lambda chimérique (1'-213') [*Rattus norvegicus* V-KAPPA (*Rattus norvegicus* IGKV22S7 (93.70%) -IGKJ1*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGLC1S1*01 V45.3>I (156) (108'-213')]; dimère (233-233":236-236")-bisdisulfure

tamtuvetmab

inmunoglobulina G2_V-kappa-C-lambda, anti-[*Homo sapiens* CD52], anticuerpo monoclonal caninizado;

cadena pesada gamma2 quimérica (1-456) [VH quimérico (*Rattus norvegicus* IGHV7S6*01 (97.00%) -(IGHD) -*Canis lupus familiaris* IGHH-E2RCC8) [8.10.12] (1-121) -*Canis lupus familiaris* IGHG2*02 (CH1 (122-219), bisagra (220-237), CH2 (238-347), CH3 (348-454), CHS (455-456))(122-456)], (136-212')-disulfuro con la cadena ligera V-kappa-C-lambda quimérica (1'-213') [*Rattus norvegicus* V-KAPPA (*Rattus norvegicus* IGKV22S7 (93.70%) -IGKJ1*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGLC1S1*01 V45.3>I (156) (108'-213')]; dímero (233-233'':236-236'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

EVKLLESGGG LVQPGGSMRL SCAGSGTFTT DFYMNWIRQP AGKAPEWLGF 50
IRDKAKGYTT EYNPSVGRGF TISRDNQNM LYLQMNTLRA EDTATYYCAR 100
EGHTAAPFDY WQGGTLVTVS SASTTAPSVF PLAPSCGSTS GSTVALACLV 150
SGYFPEPVTY SWNSGSLTSG VHTFPPSVLQS SGLYSLSSMV TVPSSRWPS 200
TFTCNVAHPA SKTKVDKPPV KRENGRVRP PDCPKCPAPE MLGGPSVFIF 250
PPKPKDTLLI ARTPEVTCVV VDLDPEDPEV QISWFFVDGKQ MQTAKTPRE 300
EQFNGTYRVV SVLPIGHQDW LKGKQFTCKV NKNALPSPIE RTISKARGQA 350
HQPSVYVLPF SREELSKNTV SLTCLIKDFF PPIDIVWQS NGQQEPESKY 400
RTTFFQLDED GSYFLYSKLS VDKSRWQRGD TFCICAVMHEA LHNHYTQKSL 450
SHSPGK 456

```

Light chain / Chaîne légère / Cadena ligera

```

DIKMTQSPSF LSASVGDRVT LNCKASQNI KYLNWYQQKL GESPKLLIYN 50
TNNLQTGIPS RFGSGSGSDT FTLTISSLQP EDVATYFCLQ HISRPRTFGG 100
GTHLTVLGQP KASPSVTLFP PSSEELGANK ATLVCLISDF YPSGVTVAWK 150
ADGSPITQGV ETTKPSKQSN NKYAASSYLS LTPDKWKSHS SFSCLVTHEG 200
STVEKKVAPA ECS 213

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-98	148-204	268-328	374-434
	22"-98"	148"-204"	268"-328"	374"-434"
Intra-L (C23-C104)	23'-88'	135'-194'		
	23'''-88'''	135'''-194'''		
Inter-H-L (CH1 11-CL 126)	136-212'	136"-212"		
Inter-H-H (h 14, h 17)	233-233"	236-236"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
304, 304"

tarloxotinibi bromidum
tarloxotinib bromide

(2*E*)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-*d*]pyrimidin-6-yl]amino]-*N,N*-dimethyl-*N*-[(1-methyl-4-nitro-1*H*-imidazol-5-yl)methyl]-4-oxobut-2-en-1-aminium bromide


bromure de tarloxotinib

bromure de (2*E*)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-*d*]pyrimidin-6-yl]amino]-*N,N*-diméthyl-*N*-[(1-méthyl-4-nitro-1*H*-imidazol-5-yl)méthyl]-4-oxobut-2-én-1-aminium

bromuro de tarloxotinib

bromuro de (2*E*)-4-[[4-(3-bromo-4-cloroanilino)pirido[3,4-*d*]pirimidin-6-il]amino]-*N,N*-dimetil-*N*-[(1-metil-4-nitro-1*H*-imidazol-5-il)metil]-4-oxobut-2-en-1-aminium

C₂₄H₂₄Br₂ClN₉O₃



tenalisibum


tenalisib

3-(3-fluorophenyl)-2-[(1*S*)-1-[(7*H*-purin-6-yl)amino]propyl]-4*H*-1-benzopyran-4-one

ténalisib

3-(3-fluorophényl)-2-[(1*S*)-1-[(7*H*-purin-6-yl)amino]propyl]-4*H*-1-benzopyran-4-one

tenalisib

3-(3-fluorofenil)-2-[(1*S*)-1-[(7*H*-purin-6-il)amino]propil]-4*H*-1-benzopiran-4-ona $C_{23}H_{18}FN_5O_2$ **tetrodotoxinum**


tetrodotoxin

(4*R*,4*aR*,5*R*,7*S*,9*S*,10*S*,10*aR*,11*S*,12*S*)-2-amino-12-(hydroxymethyl)-1,4,4*a*,5,9,10-hexahydro-7*H*-5,9:7,10*a*-dimethano[1,3]dioxocino[6,5-*d*]pyrimidine-4,7,10,11,12-pentol

tétródotoxine

(4*R*,4*aR*,5*R*,7*S*,9*S*,10*S*,10*aR*,11*S*,12*S*)-2-amino-12-(hydroxyméthyl)-1,4,4*a*,5,9,10-hexahydro-7*H*-5,9:7,10*a*-diméthano[1,3]dioxocino[6,5-*d*]pyrimidine-4,7,10,11,12-pentol

tetrodotoxina

(4*R*,4*aR*,5*R*,7*S*,9*S*,10*S*,10*aR*,11*S*,12*S*)-2-amino-12-(hidroximetil)-1,4,4*a*,5,9,10-hexahidro-7*H*-5,9:7,10*a*-dimetano[1,3]dioxocino[6,5-*d*]pirimidina-4,7,10,11,12-pentol $C_{11}H_{17}N_3O_8$ **tezacaftorum**

tezacaftor


1-(2,2-difluoro-2*H*-1,3-benzodioxol-5-yl)-*N*-{1-[(2*R*)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1*H*-indol-5-yl}cyclopropane-1-carboxamide

tezacaftor

1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide

tezacaftor

1-(2,2-difluoro-2H-1,3-benzodioxol-5-il)-N-{1-[(2R)-2,3-dihydroxiopropil]-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1H-indol-5-il}ciclopropano-1-carboxamida

$$\text{C}_{26}\text{H}_{27}\text{F}_3\text{N}_2\text{O}_6$$


timolumabum #
timolumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* AOC3 (amine oxidase copper containing 3 (EC 1.4.3.21), vascular adhesion protein 1, VAP1, VAP-1)], *Homo sapiens* monoclonal antibody;
gamma4 heavy chain (1-444) [*Homo sapiens* VH (IGHV3-30*01 (91.80%) - (IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG4*01 (CH1 (118-215), hinge S10>P (225) (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214'))]; dimer (223-223":226-226")-bisdisulfide

timolumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* AOC3 (amine oxydase à cuivre 3 (EC 1.4.3.21), VAP-1, protéine d'adhérence vasculaire 1, VAP1, VAP-1)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma4 (1-444) [*Homo sapiens* VH (IGHV3-30*01 (91.80%) - (IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG4*01 (CH1 (118-215), charnière S10>P (225) (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214'))]; dimère (223-223":226-226")-bisdisulfure

timolumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* AOC3 (amina oxidasa con cobre 3 (EC 1.4.3.21), proteína de adhesión vascular 1, VAP1, VAP-1)], *Homo sapiens* anticuerpomonoclonal ;

cadena pesada gamma4 (1-444) [*Homo sapiens* VH (IGHV3-30*01 (91.80%) -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -IGHG4*01 (CH1 (118-215), bisagra S10>P (225) (216-227), CH2 L1.2>A (232) (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* (V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214'))]; dimer (223-223":226-226")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
QVQLVSSGGG VVQPGRSRLR SCAASGFTFF SYAMHWVRQT PGKGLEWVAV 50
IWFDSGSENY VDSVKGRFTI SRDNSKNTLY LQMNTLRAED TAVYYCARD 100
WSYFDYWGQG TLVTVSSAST KGPSVFPLAP CSRSTSESTA ALGCLVKRDF 150
PEPFTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVP SSGLTKTYTC 200
NVDHKPSNTR VDKRVESKYG PPCPPCPAPE FAGGFSVFLF PPKPKDTLMI 250
SRTPEVTCTV VDVSDQDPEV QFNWYVDGVE VHNAKTKPE EQFNSTYRVV 300
SVLTVLHQDW LNKKEYKCKV SNKGLPSSIE KTISKARGQP REPQVYTLFP 350
SQEEMTKNQV SLTCLVKGFY PSDIAVWES NGQPENNYKT TFPVLDSDGS 400
FFLYSLRLTD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL SLGK 444
```

Light chain / Chaîne légère / Cadena ligera

```
VIQLTQSPSS LSASVGDRTV ITCRASQGIS RALAWYQQPK GKGPKLLIYD 50
ASSLESGVPS RFGSGSGSTD FTLTISSLQP EDFATYYCQQ FNSYPLTFGG 100
GTRVEIKRTV AAPSVFIFFP SDEQLKSGTA SVVCLLNNEY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYEKKH VYACEVTHQG 200
LSSPVTKSFN RGE 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	144-200	258-318	364-422
	22"-96"	144"-200"	258"-318"	364"-422"
Intra-L (C23-C104)	23'-88"	134'-194"		
	23'''-88'''	134'''-194'''		
Inter-H-L (CH1 10-CL 126)	131-214'	131"-214"		
Inter-H-H (h 8, h 11)	223-223"	226-226"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

294, 294"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

vadadustatum

vadadustat


[5-(3-chlorophenyl)-3-hydroxypyridine-2-carboxamido]acetic acid

vadadustat

acide [5-(3-chlorophényl)-3-hydroxypyridine-2-carboxamido]acétique

vadadustat

ácido [5-(3-clorofenil)-3-hidroxipiridina-2-carboxamido]acético

C₁₄H₁₁ClN₂O₄**vadastuximabum #**

vadastuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)], chimeric monoclonal antibody;
gamma1 heavy chain (1-447) [*Mus musculus* VH (IGHV1-85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) -*Homo sapiens* IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2

	S3>C (239) (231-340),CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with kappa light chain (1'-214') [<i>Mus musculus</i> V-KAPPA (IGKV14-111*01 - IGKJ1*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01, Km3 (108'-214')]; dimer (226-226":229-229")-bisdisulfide
vadastuximab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> CD33 (lectine 3 de type Ig-like liant l'acide sialique, SIGLEC3, SIGLEC-3, gp67, p67)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-447) [<i>Mus musculus</i> VH (IGHV1-85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) - <i>Homo sapiens</i> IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 S3>C (239) (231-340),CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Mus musculus</i> V-KAPPA (IGKV14-111*01 -IGKJ1*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01, Km3 (108'-214')]; dimère (226-226":229-229")-bisdisulfure
vadastuximab	inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> CD33 (lectina de tipo inmunoglobulina 3 que se une al ácido siálico, SIGLEC3, SIGLEC-3, gp67, p67)], anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-447) [<i>Mus musculus</i> VH (IGHV1-85*01 -(IGHD) -IGHJ4*01) [8.8.10] (1-117) - <i>Homo sapiens</i> IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-230), CH2 S3>C (239) (231-340),CH3 (341-445), CHS (446-447)) (118-447)], (220-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Mus musculus</i> V-KAPPA (IGKV14-111*01 -IGKJ1*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01, Km3 (108'-214')]; dímero (226-226":229-229")-bisdisulfuro
	Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VKKPGASVKV SCKASGYTFT NYDINWVRQA PGQGLEWIGW 50 IYPGDGSKY NEKFRKAKTL TADTSTSTAY MELRSLRSD TAVYCASGY 100 EDAMDYWGQG TTVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVTVVPS SSLGTQTYIC 200 NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP APELLGGPCV FLFPKPKDT 250 LMISRTPEVT CVVVDVSHED PEVKENWYVD GVEVHNARTK PREEQYNSTY 300 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTSKAK GPQPEQYVYT 350 LPSPRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPPVLD 400 DGSFFLYSKL TVDKSRWQGG NVFSCSYMHE ALHNHYTQKS LSLSPGK 447 Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT INCKASQDIN SYLSWFGQKP GKAPKILYR 50 ANRLVDGVPS RFGSGSGSQD YTLTISSLOP EDFATYCYLQ YDEFPLTFGG 100 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYERKK VYACEVTHQG 200 LSSPVTKSFN RGEK 214 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 144-200 261-321 367-425 22"-96" 144"-200" 261"-321" 367"-425" Intra-L (C23-C104) 23"-88" 134"-194" 23"-88" 134"-194" Inter-H-L (h 5-CL 126) 220-214' 220"-214" Inter-H-H (h 11, h 14) 226-226" 229-229" N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2N84.4: 297, 297" Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes Fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales N-terminal pyroglutamylation (pE) by cyclisation of the N-terminal glutaminyl (Q) H VH Q1>pE: 1, 1" C-terminal trimming of the C-terminal lysine (K) H CHSK2: 447, 447"

venglustatum


venglustat

(3*S*)-1-azabicyclo[2.2.2]octan-3-yl *N*-{2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl}carbamate

venglustat

N-{2-[2-(4-fluorophényl)-1,3-thiazol-4-yl]propan-2-yl}carbamate de (3*S*)-1-azabicyclo[2.2.2]octan-3-yle

venglustat

N-{2-[2-(4-fluorofenil)-1,3-tiazol-4-il]propan-2-il}carbamat de (3*S*)-1-azabicyclo[2.2.2]octan-3-iloC₂₀H₂₄FN₃O₂S**verdiperstatum**


verdiperstat

1-[2-(propan-2-yloxy)ethyl]-2-sulfanylidene-1,2,3,5-tetrahydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one

verdiperstat

1-[2-(propan-2-yloxy)éthyl]-2-sulfanylidène-1,2,3,5-tétrahydro-4*H*-pyrrolo[3,2-*d*]pyrimidin-4-one

verdiperstat

1-[2-(propan-2-iloxi)etil]-2-sulfanilideno-1,2,3,5-tetrahydro-4*H*-pirrolo[3,2-*d*]pirimidin-4-onaC₁₁H₁₅N₃O₂S**vobarilizumabum #**

vobarilizumab

immunoglobulin scFv VH-VH', anti-[*Homo sapiens* IL6R (interleukin 6 receptor, IL-6R, CD126)] and anti-[*Homo sapiens* ALB (albumin, human serum albumin, HSA)], humanized monoclonal antibody bispecific single chain; scFv (1-245) [humanized VH anti-IL6R (*Homo sapiens*IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1-121) -9-mer tetraglycyl-seryl-triglycyl-seryl linker (122-130) -humanized VH' anti-ALB (*Homo sapiens* IGKV3-23*04 (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)]

vobarilizumab

immunoglobuline scFv VH-VH', anti-[*Homo sapiens* IL6R (récepteur de l'interleukine 6, IL-6R, CD126)] et anti-[*Homo sapiens* ALB (albumine, sérum-albumine humaine, SAH)], anticorps monoclonal humanisé et bispécifique à chaîne unique; scFv (1-245) [VH humanisé anti-IL6R (*Homo sapiens*IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1-121) -9-mer tétraglycyl-séryl-triglycyl-séryl linker (122-130) -VH' humanisé anti-ALB (*Homo sapiens* IGKV3-23*04 (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)]

vobarilizumab

inmunoglobulina scFv VH-VH', anti-[*Homo sapiens* IL6R (receptor de la interleukina 6, IL-6R, CD126)] y anti-[*Homo sapiens* ALB (albúmina, albúmina sérica humana, ASH)], anticuerpo monoclonal humanizado biespecífico monocatenario;
scFv (1-245) [VH humanizado anti-IL6R (*Homo sapiens* IGHV3-66*01 (83.30%) -(IGHD) -IGHJ4*01) [8.7.15] (1-121) -9-mer tetraglicil-seril-triglicil-seril vínculo (122-130) -VH' humanizado anti-ALB (*Homo sapiens* IGKV3-23*04 (89.60%) -(IGHD) -IGHJ1*01) [8.8.9] (131-245)]

```
EVQLVESGGG LVQPGGSLRL SCAASGSVFK INVMAWYRQA PGKGREL VAG 50
IISGGSTSYA DSVKGRFTIS RDNAKNTLYL QMNSLRPEDT AVYYCAFITT 100
ESDYDLGRRY WGQGTILVTVS SGGGSGGGGS EVQLVESGGG LVQPGNSLRL 150
SCAASGFTFS SFGMSWVRQA PGKGLEWVSS ISGSGSDTLY ADSVKGRFTI 200
SRDRAKTTLY LQMNSLRPED TAVYYCTIGG SLRSGSQGTL VTVSS 245
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-chain C23 C104 22-95 152-226

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
None

xentuzumabum #
xentuzumab

immunoglobulin G1-lambda1, anti-[*Homo sapiens* IGF1 (insulin-like growth factor 1, somatomedin C) and IGF2 (insulin-like growth factor 2, somatomedin A)], humanized monoclonal antibody;
gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfide with lambda1 light chain (1'-216') [humanized V-LAMBDA (*Homo sapiens* IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC2*01 A43>G (154) (111'-216')]; dimer (226-226'':229-229'')-bisdisulfide

xentuzumab

immunoglobuline G1-lambda1, anti-[*Homo sapiens* IGF1 (facteur de croissance 1 analogue à l'insuline, somatomédine C) et IGF2 (facteur de croissance 2 analogue à l'insuline, somatomédine A)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfure avec la chaîne légère lambda1 (1'-216') [V-LAMBDA humanisé (*Homo sapiens* IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC2*01 A43>G (154) (111'-216')]; dimère (226-226'':229-229'')-bisdisulfure

xentuzumab

inmunoglobulina G1-lambda1, anti-[*Homo sapiens* IGF1 (factor de crecimiento 1 análogo a la insulina, somatomedina C) y IGF2 (factor de crecimiento 2 análogo a la insulina, somatomedina A)], anticuerpo monoclonal humanizado;

cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV3-23*03 (88.80%) -(IGHD) -IGHJ5*01) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-215')-disulfuro con la cadena ligera lambda1 (1'-216') [V-LAMBDA humanizado (*Homo sapiens* IGLV1-40*01 (88.20%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC2*01 A43>G (154) (111'-216')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVELVESGGG	LVQPGGSLRL	SCAASGFTFT	SYWMSWVRQA	PGKGLELVSS	50
ITSYGSFTYY	ADSVKGRFTI	SRDNSKNTLY	LQMNSLRAED	TAVYYCARNM	100
YTHFDSWGQG	TLTVSSAST	KGPSVFPLAP	SSKSTSGGTA	ALGCLVKDYF	150
PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVTVTPS	SSLGTQTYIC	200
NVNHKPSNTK	VDKKVEPKSC	DKTHTCPPCP	APELLGGPSV	FLFPPKPKDT	250
LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY	300
RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	350
LPFSRDELTK	NQVSLTCLVK	GFYPSTDAVE	WESNGQPENN	YKTTTPVLDS	400
DGSFFLYSKL	TVDKSRWQGG	NVFSCSVMEH	ALHNHYTQKS	LSLSPGK	447

Light chain / Chaîne légère / Cadena ligera

DIVLTQPPSV	SGAPGQRVTI	SCSGSSSNIG	SNSVSWYQQL	PGTAPKLLIY	50
DNSKRPSGVP	DRFSGSKSGT	SASLAITGLQ	SEDEADYYCQ	SRDTYGYWV	100
FGGGTKLTVL	GQPKAAPSVT	LFPPSSSEELQ	ANKATLVCLI	SDFYPGAVTV	150
AWKGDSSPVK	AGVETTPPSK	QSNKNYAASS	YLSLTPEQWK	SHRSYSCQVT	200
HEGSTVEKTV	APTECS				216

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104)	22-96	144-200	261-321	367-425
	22"-96"	144"-200"	261"-321"	367"-425"
Intra-L (C23-C104)	22'-89'	138'-197'		
	22'''-89'''	138'''-197'''		
Inter-H-L (h 5-CL 126)	220-215'	220"-215"		
Inter-H-H (h 11, h 14)	226-226'	229-229"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

297, 297"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

zoliflodacinum

zoliflodacin

(2'*R*,4'*S*,4'*aS*)-11'-fluoro-2',4'-dimethyl-8'-[(4*S*)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]-1',2',4',4'-a-tetrahydro-6'*H*-spiro[1,3-diazinane-5,5'-[1,4]oxazino[4,3-*a*][1,2]oxaz-olo[4,5-*g*]quinoline]-2,4,6-trione


zoliflodacine

(2'*R*,4'*S*,4'*aS*)-11'-fluoro-2',4'-diméthyl-8'-[(4*S*)-4-méthyl-2-oxo-1,3-oxazolidin-3-yl]-1',2',4',4'-a-tétrahydro-6'*H*-spiro[1,3-diazinane-5,5'-[1,4]oxazino[4,3-*a*][1,2]oxaz-olo[4,5-*g*]quinoline]-2,4,6-trione

zoliflodacina

(2'*R*,4'*S*,4'*aS*)-11'-fluoro-2',4'-dimetil-8'-[(4*S*)-4-metil-2-oxo-1,3-oxazolidin-3-il]-1',2',4',4'-a-tetrahidro-6'*H*-spiro[1,3-diazinano-5,5'-[1,4]oxazino[4,3-*a*][1,2]oxaz-olo[4,5-*g*]quinolina]-2,4,6-triona

C₂₂H₂₂FN₅O₇



**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Nonproprietary Names (Rec. INN): List 59
Dénominations communes internationales recommandées (DCI Rec.): Liste 59
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 59
(WHO Drug Information, Vol. 22, No. 1, 2008)

p. 58 lonaprisanum

lonaprisan
lonaprisan
lonaprisán

replace the chemical name by the following one
remplacer le nom chimique par le suivant
sustitúyase el nombre químico por el siguiente

11β-(4-acetylphenyl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-pregna-4,9-dien-3-one

11β-(4-acétylphényl)-20,20,21,21,21-pentafluoro-17-hydroxy-19-nor-17α-prégna-4,9-dién-3-one

11β-(4-acetylfenil)-20,20,21,21,21-pentafluoro-17-hidroxi-19-nor-17α-pregna-4,9-dien-3-ona

Recommended International Nonproprietary Names (Rec. INN): List 67
Dénominations communes internationales recommandées (DCI Rec.): Liste 67
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67
(WHO Drug Information, Vol. 26, No. 1, 2012)

p. 58 daclatasvirum

daclatasvir
daclatasvir
daclatasvir

replace the chemical name by the following one
remplacer le nom chimique par le suivant
sustitúyase el nombre químico por el siguiente

dimethyl *N,N'*-([1,1'-biphenyl]-4,4'-diylbis{1*H*-imidazole-5,2-diyl-[(2*S*)-pyrrolidine-2,1-diyl][(2*S*)-3-methyl-1-oxobutane-1,2-diyl]})dicarbamate
N,N'-([1,1'-biphényl]-4,4'-diylbis{1*H*-imidazole-5,2-diyl-[(2*S*)-pyrrolidine-2,1-diyl][(2*S*)-3-méthyl-1-oxobutane-1,2-diyl]})dicarbamate de diméthyle

N,N'-([1,1'-bifenil]-4,4'-diilbis{1*H*-imidazol-5,2-diil-[(2*S*)-pirrolidina-2,1-diil][(2*S*)-3-metil-1-oxobutano-1,2-diil]})dicarbamato de dimetilo

Recommended International Nonproprietary Names (Rec. INN): List 71

Dénominations communes internationales recommandées (DCI Rec.): Liste 71
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 71
(WHO Drug Information, Vol. 28, No. 1, 2014)

p. 90 **idarucizumabum**

- 91 idarucizumab
idarucizumab
idarucizumab

replace the description by the following one
remplacer la description par la suivante
sustitúyase la descripción por la siguiente

immunoglobulin Fab G1-kappa, anti-[dabigatran], humanized monoclonal antibody;
VH-(CH1-hinge) gamma1 heavy chain (1-225) [humanized VH (*Homo sapiens* IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) - *Homo sapiens* IGHG1*01 (CH1 (123-220), hinge 1-5 (221-225)) (123-225)], (225-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]

immunoglobuline Fab G1-kappa, anti-[dabigatran], anticorps monoclonal humanisé;
chaîne lourde VH-(CH1-charnière) gamma1 (1-225) [VH humanisé(*Homo sapiens* IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16](1-122) -*Homo sapiens* IGHG1*01 (CH1 (123-220), charnière 1-5 (221-225)) (123-225)], (225-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]

inmunoglobulina Fab G1-kappa, anti-[dabigatrán], anticuerpo monoclonal humanizado;
cadena pesada VH-(CH1-bisagra) gamma1 (1-225) [VH humanizado (*Homo sapiens* IGHV4-59*01 (82.30%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -*Homo sapiens* IGHG1*01 (CH1 (123-220), bisagra 1-5 (221-225)) (123-225)], (225-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (*Homo sapiens* IGKV2-30*01 (88.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.